[{"text": "Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025 Corbus Pharmaceuticals Holdings, Inc. Wed, Jan 8, 2025, 4:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. NORWOOD, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), today announced data from its first-in-human dose escalation clinical study conducted in the United States and the United Kingdom (\u201cWestern study\u201d) of CRB-701 (SYS6002) will be presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), to be held in San Francisco, CA February 13\u201315, 2025. The poster is titled Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701 (SYS6002) in US And UK Patients with Urothelial Cancer and other Solid Tutors (Perez, et al) and will be presented on Friday February 14, 2025 [Poster Session B: Urothelial Carcinoma; Poster BD# G30]. The three-part Phase 1 study ( NCT06265727 ) is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors associated with high Nectin-4 expression. The Part A dose escalation of the study evaluated four predetermined doses (1.8 mg/kg, 2.7 mg/kg, 3.6 mg/kg and 4.5 mg/kg Q3W) and is followed by Part B (dose optimization) and Part C (dose expansion) that will determine recommended/optimized doses and seek preliminary efficacy signals. About CRB-701 CRB-701 (SYS6002) is a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4, that contains a site-specific, cleavable linker and a homogenous drug antibody ratio of 2, using MMAE as the payload. Nectin-4 is a clinically validated, tumor-associated antigen in urothelial cancer. About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Story Continues These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals Sean.moran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2025-01-08T16:00:00", "sentiment": {"score": 0.06445076875388622, "confidence": 0.07754044979810715, "probabilities": {"positive": 0.07754044979810715, "negative": 0.013089681044220924, "neutral": 0.9093698859214783}}, "embedding": [-0.020239170640707016, -0.12179963290691376, -0.06542743742465973, -0.19168472290039062, -0.0874020904302597, -0.08536964654922485, -0.06735332310199738, 0.24436528980731964, -0.01418811921030283, 0.07624150067567825, -0.16670861840248108, -0.016664784401655197, 0.0854794830083847, 0.14182010293006897, -0.07178188860416412, 0.09307374060153961, 0.0035590454936027527, -0.03395107015967369, -0.0017564818263053894, 0.01264597475528717, 0.0014171674847602844, -0.021744880825281143, -0.06683750450611115, 0.05024246498942375, -0.008950486779212952, -0.1810244619846344, -0.10454732179641724, 0.05106285959482193, -0.1315944492816925, 0.011276625096797943, 0.03196554630994797, 0.03141208738088608, -0.16150027513504028, 0.010077742859721184, 0.03243369236588478, -0.09845084697008133, -0.10645836591720581, -0.013867850415408611, -0.09390240907669067, -0.00047594401985406876, -0.05436299741268158, 0.02650558203458786, -0.07963556051254272, 0.11820806562900543, 0.03603370860219002, -0.1919911950826645, -0.23462018370628357, -0.015430299565196037, 0.07355919480323792, 0.18374121189117432, -0.04912656918168068, 0.039907097816467285, -0.16399842500686646, 0.3356689214706421, 0.05627203732728958, -0.0532124899327755, -0.19711558520793915, -0.0031512032728642225, 0.13764463365077972, -0.022226482629776, -0.11454378813505173, -0.13899356126785278, 0.18077316880226135, -0.017981059849262238, 0.05920504033565521, -0.014889041893184185, -0.08330953121185303, -0.0464262031018734, -0.06620202958583832, 0.05044512450695038, 0.08373157680034637, -0.036182478070259094, -0.040400706231594086, 0.056442901492118835, -0.07643939554691315, 0.026871807873249054, 0.03178684040904045, 0.1902811974287033, 0.032418254762887955, -0.16971167922019958, 0.04870247840881348, 0.08194708824157715, 0.15578728914260864, -0.08870016038417816, 0.018147043883800507, 0.0014685913920402527, -0.010440999642014503, 0.11046718060970306, 0.083671934902668, 0.09892058372497559, 0.2428918480873108, 0.19526821374893188, -0.012914177030324936, 0.04484579712152481, 0.06885405629873276, -0.057202182710170746, -0.06556101888418198, 0.07289652526378632, -0.0546458438038826, 0.015448245219886303, -0.016787737607955933, 0.04990974813699722, -0.08598679304122925, -0.13757437467575073, 0.08242808282375336, -0.06830468773841858, 0.00599572341889143, 0.16880738735198975, -0.07339740544557571, -0.012254307977855206, -0.013193138875067234, 0.011115485802292824, 0.10059992969036102, -0.10804038494825363, -0.008839013054966927, 0.15394531190395355, -0.007726434618234634, -0.046888258308172226, 0.12636303901672363, -0.07884201407432556, 0.08902381360530853, -0.02431938610970974, 0.07805746793746948, -0.0939500480890274, 0.09032362699508667, 0.1339436024427414, -0.002275735605508089, 8.52963533274813e-33, 0.030408266931772232, -0.022305509075522423, 0.14223653078079224, 0.07509560883045197, -0.08296705782413483, -0.035091932862997055, 0.03664863109588623, 0.03976159542798996, -0.12280204892158508, -0.2301689088344574, -0.1259768307209015, 0.059934914112091064, -0.01966700330376625, 0.029864897951483727, -0.12035674601793289, -0.08989305794239044, -0.001422985689714551, 0.0027487361803650856, -0.11152209341526031, -0.11386001110076904, 0.003505227155983448, 0.06129249557852745, -0.0922158733010292, 0.06666591763496399, -0.09145332872867584, -0.01403550710529089, -0.04244501143693924, 0.16430498659610748, -0.06897423416376114, 0.026909412816166878, -0.13680163025856018, 0.055080268532037735, 0.0068592652678489685, -0.08322583884000778, -0.07951551675796509, -0.048466891050338745, -0.08725085854530334, -0.11620497703552246, -0.06914813816547394, 0.13834884762763977, 0.12697738409042358, -0.008228309452533722, 0.03405093401670456, -0.1614684760570526, 0.14340943098068237, -0.11832328885793686, -0.03717494755983353, 0.012572672218084335, -0.08465929329395294, 0.08481431752443314, -0.050642117857933044, -0.07671137154102325, -0.06183529272675514, 0.02823016792535782, -0.055358290672302246, -0.042528726160526276, -0.13999804854393005, -0.09756600111722946, 0.1611858308315277, 0.03801332041621208, 0.05104193091392517, -0.029027916491031647, -0.057186439633369446, 0.07742157578468323, -0.03107517771422863, 0.0357666090130806, -0.10814107209444046, -0.08332260698080063, -0.019060079008340836, 0.01589823141694069, -0.05485355108976364, -0.08200191706418991, 0.19268798828125, -0.0008051590994000435, 0.14065060019493103, -0.03386904299259186, 0.14003996551036835, 0.04345224052667618, -0.08106797933578491, 0.059214986860752106, -0.00684033427387476, 0.011466327123343945, -0.1060979962348938, 0.1250687539577484, 0.0459885373711586, -0.1709699034690857, 0.002995699644088745, -0.11814819276332855, -0.15636196732521057, 0.01275181956589222, 0.0613483190536499, -0.02844325080513954, -0.18619583547115326, 0.15524400770664215, -0.040428176522254944, -8.001237397742064e-33, 0.03559581935405731, 0.012109976261854172, 0.10680955648422241, 0.06397110223770142, -0.015405915677547455, 0.17705859243869781, 0.2632385492324829, -0.17774230241775513, 0.16898725926876068, -0.15537585318088531, 0.13192152976989746, 0.05440116673707962, -0.03124810755252838, -0.12534168362617493, -0.0667729452252388, 0.028141075745224953, -0.09425956010818481, -0.007520374841988087, -0.11073362827301025, 0.11504621058702469, 0.006682104431092739, 0.10633067041635513, -0.11270065605640411, 0.016233840957283974, -0.01623046211898327, 0.0236334390938282, 0.08717547357082367, -0.03432184457778931, 0.11292432248592377, 0.008862432092428207, 0.0581703707575798, -0.01435148250311613, -0.16430678963661194, 0.13160721957683563, -0.11035409569740295, -0.13064852356910706, 0.14752349257469177, -0.16341134905815125, 0.04616422951221466, -0.09209275245666504, 0.03432197868824005, 0.11350147426128387, -0.04739290848374367, -0.07104617357254028, -0.04871252179145813, 0.10986494272947311, 0.1184048280119896, 0.0596565380692482, 0.05402647703886032, -0.03394896537065506, 0.000852641649544239, 0.009991249069571495, 0.021851535886526108, 0.04926009476184845, -0.012862849980592728, 0.01679583638906479, -0.08194415271282196, -0.005428961478173733, -0.01663406379520893, 0.09105082601308823, 0.12652339041233063, 0.13488876819610596, 0.10640188306570053, -0.06834962218999863, 0.13468126952648163, 0.16946299374103546, -0.007373874541372061, 0.08362071216106415, 0.004310212563723326, -0.14244791865348816, -0.1319931149482727, -0.05276889353990555, 0.008172810077667236, -0.11821442097425461, 0.10190635174512863, -0.005566624458879232, 0.006722877733409405, -0.13893577456474304, -0.08749093860387802, -0.01962161436676979, -0.06977149844169617, -0.08209779113531113, -0.05623409524559975, 0.04057633504271507, 0.027194304391741753, 0.10446031391620636, -0.04853764921426773, 0.01758476346731186, 0.0411360040307045, 0.02175309881567955, -0.156113862991333, -0.07117029279470444, -0.05789284408092499, 0.17575763165950775, -0.004531063139438629, -9.97334979047082e-08, 0.0284599456936121, 0.017333880066871643, 0.11370088160037994, -0.14987142384052277, 0.10780653357505798, 0.04970724880695343, -0.02274727076292038, -0.02637425623834133, -0.05983688309788704, 0.15822471678256989, 0.05141966789960861, 0.048426881432533264, -0.1025761216878891, -0.04318080469965935, -0.13921654224395752, 0.12429942190647125, -0.011098905466496944, -0.06409783661365509, -0.008492238819599152, 0.0844021663069725, -0.05080685392022133, -0.06458646059036255, 0.07927712053060532, 0.07306647300720215, 0.10423502326011658, -0.04397580400109291, -0.013133605942130089, 0.1853674203157425, 0.023853741586208344, -0.02446908876299858, -0.029214460402727127, -0.0540507547557354, 0.07673801481723785, -0.010866192169487476, -0.024061646312475204, 0.06629706919193268, 0.03609918802976608, 0.09590914845466614, 0.06413162499666214, 0.1743592470884323, 0.13542036712169647, -0.027436107397079468, 0.05973866581916809, -0.02309603989124298, -0.002908671274781227, -0.015915503725409508, -0.12449230253696442, 0.09712569415569305, -0.1649283766746521, -0.017733832821249962, 0.0245212409645319, 0.06570633500814438, -0.11322852224111557, -0.07786084711551666, 0.024221064522862434, 0.06102323159575462, -0.04539705067873001, -0.06546229124069214, 0.1275341808795929, -0.069106824696064, 0.08048607409000397, -0.03494375944137573, 0.05841335281729698, 0.09286600351333618], "changes": {"1wk": -7.95819778546697}}, {"text": "Corbus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference Corbus Pharmaceuticals Holdings, Inc. Mon, Jan 6, 2025, 4:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. NORWOOD, Mass., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will be participating in the 43 rd Annual J.P. Morgan Healthcare Conference, to be held January 13-16, 2025 in San Francisco, CA. Dr. Cohen will be presenting and attending investor meetings. 43 rd Annual J.P. Morgan Healthcare Conference Format: Presentation and one-on-one investor meetings Presentation Date: January 16, 2025 Presentation Time 11:15 a.m. PST The J.P. Morgan Healthcare Conference is invitation only. Those interested in attending should contact their J.P. Morgan representative for more information. About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Story Continues All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals Sean.moran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2025-01-06T16:00:00", "sentiment": {"score": 0.0442737964913249, "confidence": 0.05529254674911499, "probabilities": {"positive": 0.05529254674911499, "negative": 0.011018750257790089, "neutral": 0.9336886405944824}}, "embedding": [-0.045249395072460175, -0.04750264063477516, -0.07599785923957825, -0.11667541414499283, -4.745647311210632e-05, 0.07894019037485123, -0.06588946282863617, 0.17899054288864136, 0.05497976019978523, -0.019021503627300262, -0.1427144706249237, 0.04741372540593147, -0.010098814964294434, 0.0023133032955229282, 0.009388206526637077, -0.033537887036800385, 0.07654466480016708, -0.022361591458320618, -0.026712089776992798, -0.025909919291734695, 0.009160690009593964, 0.05945325642824173, 0.045259989798069, 0.06920473277568817, -0.15391919016838074, -0.09220637381076813, -0.02168155089020729, -0.04058772325515747, -0.2022954523563385, 0.04012781381607056, 0.023632053285837173, 0.0501040518283844, -0.02571219950914383, -0.030543847009539604, 0.026464443653821945, 0.010713478550314903, -0.07742875814437866, -0.024293510243296623, 0.10442612320184708, 0.012661624699831009, -0.022884156554937363, 0.0783541202545166, -0.03265423700213432, 0.10460017621517181, 0.06946875900030136, -0.16545701026916504, -0.1559557318687439, 0.05535212159156799, 0.041398726403713226, 0.06592642515897751, -0.10517621040344238, -0.052716244012117386, -0.05551275610923767, 0.13316529989242554, -0.07861674576997757, 0.15259119868278503, -0.2556819021701813, -0.01767398603260517, 0.14109185338020325, -0.07043932378292084, -0.027338281273841858, 0.06487036496400833, 0.17401030659675598, 0.19650883972644806, 0.10598815977573395, 0.0934683308005333, -0.02462841384112835, 0.030481792986392975, 0.04242178797721863, -0.027841081842780113, 0.14940492808818817, -0.11058017611503601, -0.1070614904165268, 0.013734913431107998, -0.05307288467884064, 0.1504649519920349, 0.04614388570189476, 0.15062233805656433, 0.10807779431343079, -0.06589128077030182, -0.01853785291314125, 0.14635881781578064, 0.16921266913414001, -0.016455236822366714, -0.10469228029251099, 0.0004989898297935724, -0.04265261068940163, 0.10905087739229202, 0.026721462607383728, 0.019919971004128456, 0.15455904603004456, -0.0352206714451313, 0.0625367984175682, 0.12548184394836426, -0.09548376500606537, -0.0991433784365654, -0.011752134189009666, -0.012851475737988949, -0.03317982703447342, 0.00353773171082139, -0.010267224162817001, 0.12844730913639069, -0.07447253912687302, -0.04700204357504845, -0.036666225641965866, -0.009027978405356407, 0.021206237375736237, 0.1273697316646576, 0.12216177582740784, 0.05636270344257355, -0.13080427050590515, 0.12366962432861328, -0.026788901537656784, -0.1418461799621582, 0.026987900957465172, 0.19467787444591522, 0.04250774532556534, 0.05376088619232178, 0.12347571551799774, -0.10303886234760284, 0.07794976979494095, -0.057384297251701355, -0.08298452198505402, -0.18298323452472687, -0.033530376851558685, 0.03773508220911026, -0.18784867227077484, 8.411987450014019e-33, 0.01284380629658699, -0.10143047571182251, 0.22386497259140015, 0.057727884501218796, 0.030550431460142136, -0.0443267896771431, 0.007382565643638372, -0.024665474891662598, -0.18229860067367554, -0.09969450533390045, -0.1552404910326004, 0.05010142922401428, 0.020031120628118515, 0.023831643164157867, -0.16119877994060516, -0.11057458817958832, -0.0555754154920578, 0.04677774757146835, 0.024549484252929688, -0.06505855172872543, -0.07629148662090302, 0.05748771131038666, 0.01281152106821537, 0.16432400047779083, 0.03964800015091896, 0.08013882488012314, -0.04031204432249069, 0.1456015706062317, 0.056319255381822586, 0.0899793803691864, -0.15090814232826233, 0.008191041648387909, -0.05739760398864746, -0.10378532111644745, -0.06912576407194138, -0.0562925785779953, -0.1209011822938919, -0.1693199872970581, -0.006571274250745773, 0.010470552369952202, -0.026110604405403137, -0.010342699475586414, -0.1118881106376648, -0.13556773960590363, 0.07938094437122345, 0.001986549235880375, -0.06591404974460602, 0.0651908740401268, -0.03212754428386688, -0.04651165381073952, -0.04041595757007599, 0.045809660106897354, -0.03768477588891983, 0.026570644229650497, -0.006540059112012386, -0.0800156220793724, -0.08353903889656067, -0.017600923776626587, 0.16462570428848267, 0.10129716247320175, 0.12218767404556274, 0.14276644587516785, -0.09167961776256561, 0.07799232006072998, -0.11444280296564102, 0.07803209871053696, -0.1570909172296524, -0.09010183811187744, -0.05190667510032654, 0.051326751708984375, 0.05623947083950043, 0.02857169136404991, 0.047321222722530365, -0.08198957145214081, 0.1558379828929901, -0.12224464118480682, 0.06085462123155594, 0.014330612495541573, -0.04099950194358826, 0.08063815534114838, 0.03642597049474716, -0.04874614626169205, -0.030335979536175728, 0.12151697278022766, 0.03421153128147125, -0.16773340106010437, 0.01936093345284462, 0.015223697759211063, -0.0371491014957428, -0.012670285999774933, 0.039183616638183594, 0.007357086054980755, -0.007898915559053421, 0.20755508542060852, -0.06295482069253922, -7.044315935879612e-33, -0.06891091167926788, -0.14357589185237885, 0.05757172405719757, -0.06654920428991318, -0.0453108549118042, 0.006325392052531242, 0.11390528082847595, -0.19880995154380798, 0.13040055334568024, -0.1667543649673462, 0.013557146303355694, -0.0010466314852237701, -0.11160701513290405, -0.05775102972984314, -0.09416648745536804, 0.10447496920824051, -0.00863887183368206, 0.017135508358478546, -0.1612222045660019, 0.06561854481697083, 0.060769304633140564, 0.12345138192176819, -0.057934753596782684, 0.0014310572296380997, -0.02165471762418747, 0.11635401099920273, 0.06047694757580757, 0.11474373191595078, 0.0726383775472641, -0.006485501769930124, -0.06857194006443024, 0.07687817513942719, -0.3006632924079895, 0.11022689938545227, -0.09390120208263397, -0.01965787447988987, 0.04558611661195755, -0.12477163970470428, 0.08253197371959686, -0.14614444971084595, 0.0936516672372818, 0.01631994917988777, -0.08695705235004425, 0.04245405271649361, 0.09034229815006256, 0.013515777885913849, 0.07470294833183289, 0.05137549340724945, 0.10740848630666733, 0.09698529541492462, -0.12618310749530792, -0.020726079121232033, 0.00325867161154747, 0.08194468915462494, -0.00764065608382225, 0.10423831641674042, -0.0583307221531868, -0.02447580173611641, 0.06875906884670258, -0.05178963392972946, -0.01103174313902855, 0.1203077882528305, -0.008695532567799091, 0.0705854669213295, 0.10155025869607925, 0.091551274061203, 0.11194618046283722, 0.11831251531839371, 0.08327839523553848, -0.16487695276737213, 0.08502042293548584, -0.07520323991775513, 0.005966614931821823, -0.050081465393304825, 0.03308635577559471, 0.05626991018652916, -0.030451834201812744, -0.08572609722614288, -0.20868650078773499, 0.08988362550735474, 0.0353303961455822, -0.06302322447299957, 0.06569679081439972, 0.08871075510978699, 0.011493874713778496, 0.1006351113319397, 0.019198037683963776, -0.024836283177137375, -0.04370725899934769, 0.05966116487979889, -0.10157045722007751, -0.09123559296131134, -0.03937036544084549, 0.15007132291793823, 0.11233878135681152, -9.910309017868713e-08, 0.04107215628027916, -0.03902667760848999, 0.0653558000922203, -0.09321700036525726, 0.08036843687295914, -0.004872193560004234, 0.00767903309315443, -0.0842791497707367, -0.01577785611152649, 0.14276748895645142, 0.1094471737742424, 0.10288727283477783, -0.12576435506343842, 0.022490620613098145, -0.14674827456474304, 0.06331536173820496, -0.19303643703460693, 0.021400753408670425, -0.005378494970500469, -0.0034018773585557938, -0.11441726237535477, -0.02984907291829586, 0.14192157983779907, 0.05947116017341614, 0.03691593557596207, -0.12403275072574615, 0.035674821585416794, 0.07766681164503098, 0.07565471529960632, 0.015006259083747864, -0.10815306007862091, 0.08273627609014511, 0.05306591838598251, -0.008648945018649101, -0.01017686165869236, -0.1548389196395874, 0.05013645812869072, 0.08067156374454498, 0.037734419107437134, 0.11818988621234894, -0.15868690609931946, -0.041226647794246674, 0.05856621265411377, 0.00722859799861908, -0.01764567382633686, -0.10254299640655518, -0.07220178842544556, 0.15812566876411438, -0.02533281035721302, -0.10859774053096771, -0.035484421998262405, -0.028065040707588196, -0.046958185732364655, -0.032117899507284164, -0.10583020746707916, 0.13429376482963562, -0.10325077921152115, -0.11390124261379242, -0.023193173110485077, -0.16027696430683136, 0.026056554168462753, -0.09966180473566055, 0.13362815976142883, 0.02529021166265011], "changes": {"1wk": -8.320371099455256}}, {"text": "Why Is Corbus Pharmaceuticals Holdings, Inc. (CRBP) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds? Laiba Immad Wed, Dec 4, 2024, 8:31 PM 6 min read In This Article: CRBP -2.86% We recently compiled a list of the 10 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds . In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) stands against the other small-cap biotech stocks. Revolutionizing Healthcare and Economy: The Rapid Growth of Biotechnology The biotechnology sector is expanding quickly due to rising demand for novel therapies, technological advances, and government assistance. Advances in fields like gene editing, sequencing, personalized medicine, and artificial intelligence are making new techniques possible, while the aging population and growing healthcare demands are driving a robust market for new treatments. According to a report by McKinsey & Company, venture capital firms made approximately $52 billion in global investments in therapeutic-focused biotech companies between 2019 and 2021. Two-thirds of this sum was given to platform-tech start-up companies. Despite its growth, many biotech companies have faced challenges in turbulent markets, taking drastic measures such as cutting programs and implementing significant layoffs to conserve cash. While recent rate cuts could encourage the revival of scientific projects, analysts like Jared Holz note the difficulty of gauging their impact. Holz also highlighted a shift in market dynamics, observing that biotech's performance increasingly correlates with small-cap equities. If small-cap stocks trade well, biotech is likely to follow, though stagnation could occur if momentum fades. Notably, the idea of interest rates predicting biotech success is relatively new, emerging only after the pandemic, which reshaped the industry by driving substantial investment into therapeutic-focused companies. With innovative treatments, biotech businesses are revolutionizing healthcare by tackling important unmet medical needs. Establishing the National Bioeconomy Board as a component of Biden's Investing in America agenda is a significant breakthrough. It seeks to maximize biotechnology's economic potential in the United States. Furthermore, policy suggestions to expedite the approval process for biotechnology goods are being developed by the National Security Commission on Emerging Biotechnology. More academics will be able to use biotechnology for agricultural purposes if entry obstacles are reduced, which will benefit American farmers and increase food security. It is anticipated that these initiatives will open up new markets. Pharmaceuticals as Defensive Investments and the 2024 Healthcare Market Outlook This year (2024) started strongly for the biotechnology sector due to a rise in mergers and acquisitions as well as anticipations of falling interest rates. Therefore, estimates suggest that the worldwide biotechnology market might increase at a compound annual growth rate (CAGR) of around 14% from 2024 to 2033, reaching an astonishing $5.7 trillion. The market for agricultural biotechnology is also expected to develop at a 7.9% compound annual growth rate (CAGR) and reach $232 billion by 2032. Story Continues But even with the market's potential, investing in biotech companies still carries a number of serious dangers. Bankruptcy may result from failing to satisfy clinical trial endpoints or obtain adequate finance before a product launch. In the biotech industry, where drug development usually takes more than ten years and has an estimated failure rate of about 90%, the danger of failure is very substantial. Hence, biotech stocks are often considered \u201chigh-risk, high-reward\u201d investments due to their upside potential coupled with significant risks Our Methodology In our methodology, we identified the top small-cap biotech stocks with significant growth potential, ranked according to their total hedge fund holdings as of Q2 2024. Our selection process began by filtering companies with a small market capitalization. Next, we reviewed analyst recommendations, focusing on stocks with strong bullish sentiment and high institutional ownership. Finally, we ranked these companies based on the number of hedge funds holding their shares as of Q2 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A biopharmaceutical scientist in a lab examining a vial of pharmaceuticals. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP ) Number of Hedge Fund Holdings: 25 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a precision oncology company focused on developing innovative therapies for cancer treatment. At its core, the company is working on creating drugs that target specific biological pathways involved in cancer growth and progression. The corporation's primary focus is on developing two key experimental drugs: CRB-701, an antibody-drug conjugate (ADC) targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that blocks TGF\u03b2 activation. These drugs are designed to treat solid tumors, with potential applications in urothelial, lung, breast, and prostate cancers. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) recently completed enrollment for the dose escalation part of its Phase 1 clinical trial for CRB-701, with data expected in early 2025. Additionally, new pre-clinical data for CRB-913 was presented at Obesity Week 2024, showing promising results in weight loss. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is recognized as a promising small-cap biotech stock with significant potential. The company has experienced fluctuations in its financial performance. For the third quarter of 2024, the corporation reported a net loss of approximately $13.8 million, compared to a net loss of $10.1 million in the same period in 2023. The increase in net loss is primarily attributed to higher operating expenses, which rose by $6.0 million due to increased clinical trial costs for CRB-701 and IND-enabling studies for CRB-913. As of Q3 2024, 25 hedge fund holders held stakes in the company with Cormorant Asset Management being the largest stakeholder with holdings worth $48.9 million, as tracked by the Insider Monkey database. Street analysts hold a consensus Strong Buy rating on the stock with an average price target of $88.00. This reflects a 78.39% increase from the current price of $49.33. Overall CRBP ranks 10th on our list of the best small-cap biotech stocks with massive potential according to hedge funds. While we acknowledge the potential of CRBP as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CRBP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-12-04T20:31:31", "sentiment": {"score": 0.5987124964594841, "confidence": 0.6177158355712891, "probabilities": {"positive": 0.6177158355712891, "negative": 0.019003339111804962, "neutral": 0.3632808029651642}}, "embedding": [0.06069859862327576, -0.13589192926883698, 0.020144063979387283, -0.10652116686105728, 0.09983426332473755, 0.03255818039178848, -0.042390622198581696, 0.14165060222148895, 0.11307103931903839, 0.10477308928966522, -0.15000909566879272, 0.09753388166427612, -0.06792902946472168, -0.009334487840533257, -0.1622093766927719, 0.006829575169831514, -0.061991095542907715, -0.03363984450697899, -0.06743094325065613, 0.11021430790424347, -0.02918900176882744, 0.015581208281219006, 0.04026034474372864, 0.049478136003017426, -0.01293070800602436, -0.047972917556762695, -0.04383694380521774, -0.09954848885536194, -0.25547876954078674, 0.014074102975428104, 0.09632185846567154, 0.14454689621925354, 0.02674028091132641, -0.060438916087150574, 0.025157269090414047, 0.11402206867933273, -0.08773931860923767, 0.06144784390926361, 0.13935142755508423, 0.013411296531558037, 0.03389262035489082, -0.07233895361423492, -0.10460212081670761, 0.09492293745279312, 0.11547331511974335, -0.14616946876049042, -0.023478932678699493, -0.03080279938876629, 0.05992696061730385, -0.0372479110956192, -0.18738913536071777, -0.15563324093818665, -0.004608468152582645, -0.04681196063756943, -0.044680893421173096, 0.029256558045744896, -0.08106604218482971, -0.051286838948726654, 0.07942767441272736, 0.06087566167116165, 0.04032953456044197, -0.07889969646930695, 0.14062269032001495, -0.032398976385593414, 0.11812317371368408, -0.07551534473896027, 0.056869637221097946, 0.10047939419746399, -0.06815066188573837, 0.06594966351985931, 0.16590063273906708, -0.07667846977710724, -0.12716621160507202, 0.07463273406028748, -0.08768070489168167, 0.10228688269853592, 0.05751011148095131, 0.25832104682922363, 0.20815511047840118, -0.05954628810286522, 0.03229079395532608, -0.0896393433213234, 0.035135701298713684, -0.04519187659025192, -0.16959717869758606, 0.0148326326161623, 0.05799068510532379, 0.07197988778352737, 0.08191098272800446, 0.015321549959480762, 0.005995351821184158, -0.05445017293095589, 0.09476271271705627, 0.05330825224518776, 0.05539923161268234, -0.04671528935432434, -0.040138453245162964, -0.016006292775273323, 0.034326840192079544, 0.0010586422868072987, 0.048470839858055115, -0.00878842081874609, -0.029287930577993393, 0.00021414458751678467, -0.04854767024517059, -0.06979132443666458, -0.004956069402396679, -0.06013200804591179, 0.14701104164123535, 0.09797071665525436, -0.09586910903453827, 0.15015563368797302, -0.10544528067111969, 0.06278132647275925, -0.06273853033781052, 0.15545883774757385, -0.00930373091250658, -0.03479926288127899, 0.14452165365219116, 0.014868262223899364, 0.033025600016117096, 0.038440193980932236, -0.08126448839902878, -0.2129989117383957, -0.1010882556438446, 0.08855363726615906, -0.1740027219057083, 9.652564514937521e-33, -0.02718132734298706, 0.06533066928386688, 0.04975723475217819, 0.018503082916140556, -0.09556885808706284, -0.02604140341281891, -0.005136278923600912, -0.04027580842375755, -0.190556138753891, -0.12602823972702026, -0.167576402425766, 0.09829718619585037, -0.04453113302588463, 0.07583063840866089, -0.0029598164837807417, -0.2082487940788269, -0.06581732630729675, 0.05055160075426102, 0.047865305095911026, -0.06747442483901978, -0.14679670333862305, 0.028632577508687973, -0.06643936038017273, 0.08563045412302017, 0.01624162308871746, -0.16231152415275574, -0.11139141023159027, -0.029760602861642838, 0.08046870678663254, 0.07340604066848755, -0.09778930246829987, 0.1156204342842102, -0.02538662776350975, -0.08343885093927383, -0.028459342196583748, -0.10274968296289444, -0.08312372863292694, -0.13984991610050201, 0.06939518451690674, 0.12519989907741547, -0.07630705833435059, 0.1049860268831253, -0.09539824724197388, -0.06034988909959793, 0.04260237514972687, 0.07278521358966827, -0.004132524598389864, 0.04915611818432808, -0.09826959669589996, -0.007898619398474693, -0.1249384731054306, 0.15013769268989563, 0.061577484011650085, -0.09249041974544525, 0.06260472536087036, -0.033069971948862076, -0.18082404136657715, -0.13576897978782654, 0.03632739186286926, 0.02198854275047779, -0.011349473148584366, 0.07110634446144104, -0.0005109088961035013, 0.12194482982158661, -0.1196196898818016, 0.22106966376304626, 0.0938635915517807, 0.08350533992052078, -0.05970695614814758, 0.2222934067249298, 0.06647562235593796, -0.09991239011287689, -0.022876059636473656, -0.03348209708929062, 0.05370544269680977, -0.0493655651807785, -0.005532203242182732, 0.057690054178237915, -0.06355130672454834, 0.08000065386295319, 0.06708917021751404, -0.0044042388908565044, -0.1325828582048416, 0.01548069342970848, 0.017025470733642578, -0.03746911510825157, 0.007336494512856007, 0.11146561801433563, 0.011337893083691597, -0.017368389293551445, -0.09633691608905792, -0.04950565844774246, -0.004110758192837238, 0.15456518530845642, -0.034738000482320786, -1.0556565955809924e-32, -0.02519770711660385, -0.12121886759996414, 0.02933580055832863, 0.0545351542532444, -0.015224217437207699, 0.002709057182073593, 0.1097414493560791, -0.18192750215530396, 0.07168157398700714, -0.09945276379585266, -0.01874229498207569, 0.05552063137292862, 0.001161785563454032, -0.010625842027366161, -0.145578071475029, 0.03366135060787201, -0.025308692827820778, -0.0862591415643692, 0.030005941167473793, -0.028731098398566246, 0.0863363966345787, 0.06467539072036743, -0.11050285398960114, 0.08308959752321243, 0.011162526905536652, 0.08214464038610458, -0.12327732145786285, 0.10277168452739716, 0.044992029666900635, -0.07434724271297455, -0.0966789573431015, 0.017527170479297638, -0.21769556403160095, 0.15467292070388794, -0.09503795951604843, 0.05219130963087082, 0.010308027267456055, -0.15217767655849457, 0.095619335770607, -0.037935905158519745, 0.11913105100393295, -0.037348806858062744, -0.07225499302148819, 0.02025226503610611, 0.005011692643165588, -0.0625183954834938, -0.03230865299701691, 0.12021556496620178, 0.1492243856191635, 0.015669550746679306, -0.03277258947491646, 0.13055716454982758, 0.06266704946756363, -0.041405074298381805, -0.1407673954963684, 0.027433540672063828, 0.05720999091863632, 0.02860187366604805, -0.10650074481964111, 0.06695928424596786, 0.036263592541217804, 0.07327352464199066, 0.018214240670204163, 0.04768341779708862, -0.08002021908760071, -0.01631578430533409, 0.11246311664581299, 0.030553316697478294, -0.07484729588031769, -0.14743837714195251, 0.05898028612136841, -0.03560899570584297, 0.08089859038591385, -0.038600627332925797, -0.03706749156117439, 0.23009100556373596, -0.044944606721401215, -0.12935760617256165, -0.13426083326339722, 0.08225446939468384, 0.07605008035898209, -0.005066500045359135, 0.08309175819158554, -0.060050155967473984, -0.032959531992673874, 0.13790151476860046, -0.06317508220672607, -0.07436948269605637, -0.10149773210287094, 0.002027193084359169, -0.12720048427581787, -0.19461825489997864, -0.0226031132042408, 0.10782573372125626, -0.015437821857631207, -1.0028666963535215e-07, 0.16078197956085205, -0.10994372516870499, 0.13666579127311707, -0.11726149916648865, 0.09956368803977966, -0.022524163126945496, -0.12343230843544006, 0.06340040266513824, 0.11448892205953598, 0.1825285255908966, 0.007323823869228363, 0.17392775416374207, -0.1670600175857544, 0.21229425072669983, -0.08715593814849854, 0.10531508177518845, -0.16803312301635742, 0.032084424048662186, -0.019061721861362457, -0.034847673028707504, -0.04047797992825508, 0.09886675328016281, 0.04876096546649933, 0.04080722853541374, 0.04967828094959259, -0.07570461928844452, 0.006327859126031399, 0.03717290610074997, -0.0046463776379823685, 0.04338635876774788, -0.008670155890285969, -0.05552983283996582, 0.06260545551776886, 0.036185309290885925, -0.009672453626990318, -0.04716351628303528, 0.024241184815764427, 0.03151114284992218, -0.030168471857905388, 0.03992018848657608, -0.00520484009757638, -0.01036542747169733, -0.01521226018667221, -0.0683424174785614, -0.05201547592878342, -0.12552860379219055, -0.0736510157585144, 0.13322116434574127, 0.08470084518194199, -0.12223415076732635, 0.08752362430095673, -0.00439625047147274, 0.013967507518827915, 0.014834249392151833, 0.02502250112593174, 0.1638624519109726, -0.08679854869842529, -0.054593272507190704, -0.08376194536685944, -0.08727136254310608, -0.04115026816725731, -0.25588053464889526, 0.15903019905090332, 0.02431204728782177], "changes": {"1wk": -1.370712297895309, "1mo": -18.75389045662523}}, {"text": "PREMIUM Corbus Pharmaceuticals' CRB-701 Gets FDA Fast Track Designation for Treatment of Cervical Cancer MT Newswires Tue, Dec 3, 2024, 4:59 PM 1 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings (CRBP) said Tuesday that CRB-701 has received fast track designation PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-12-03T16:59:19", "sentiment": {"score": 0.07269938942044973, "confidence": 0.08357610553503036, "probabilities": {"positive": 0.08357610553503036, "negative": 0.010876716114580631, "neutral": 0.9055472016334534}}, "embedding": [-0.118593230843544, -0.08443780243396759, -0.1416875571012497, -0.07040826231241226, 0.09251920878887177, 0.023150775581598282, -0.07611655443906784, 0.1444280743598938, -0.07006826251745224, -0.0045624603517353535, -0.0039059962145984173, 0.033225659281015396, 0.06522054970264435, -0.03295736759901047, -0.08588128536939621, -0.06668880581855774, 0.17625226080417633, -0.13268524408340454, 0.17092090845108032, -0.012620214372873306, -0.2778487801551819, 0.08008009195327759, -0.000998303759843111, 0.09927581995725632, 0.05652681365609169, -0.15149743854999542, -0.192040354013443, 0.01150814164429903, -0.004809955600649118, 0.020745573565363884, 0.16369947791099548, -0.007108478806912899, -0.006444692146033049, -0.02138247713446617, -0.015466712415218353, -0.1381557285785675, -0.05066012218594551, -0.09216958284378052, -0.018154682591557503, 0.07178614288568497, 0.14465464651584625, -0.11227653175592422, -0.09014491736888885, 0.18179525434970856, 0.0513584166765213, -0.14243154227733612, -0.1529882699251175, 0.0312526635825634, 0.011001712642610073, 0.036482442170381546, -0.06170959025621414, -0.26924121379852295, -0.12069110572338104, 0.1367236226797104, 0.02391146309673786, 0.05048814043402672, -0.24282951653003693, 0.0065221358090639114, 0.0898192971944809, 0.0048608845099806786, -0.100782610476017, -0.11061770468950272, 0.12098348885774612, 0.1602438986301422, 0.01742636226117611, 0.08081508427858353, 0.0329708494246006, -0.018519293516874313, -0.04686634987592697, -0.05198242515325546, 0.007507631089538336, 0.022831587120890617, -0.06117710471153259, 0.12950171530246735, 0.04405711963772774, 0.04788430407643318, -0.0072388965636491776, 0.09480138123035431, 0.04522727057337761, -0.17420080304145813, 0.0005696843727491796, 0.027132008224725723, 0.1993110626935959, 0.004111056216061115, 0.01908341981470585, -0.030464692041277885, 0.05622768774628639, 0.05028816685080528, -0.03167043253779411, -0.1023421436548233, 0.3468179404735565, -0.04005195572972298, 0.10387371480464935, 0.06744760274887085, -0.2198110967874527, 0.08362855762243271, -0.1494307518005371, -0.04946937412023544, -0.1820644587278366, -0.04801530763506889, -0.17168930172920227, 0.05962301418185234, -0.11477424949407578, 0.03769749030470848, -0.052026741206645966, -0.1254686713218689, -0.003359021618962288, 0.2779249846935272, -0.055817026644945145, 0.0880810096859932, 0.009107128717005253, 0.14985591173171997, 0.0546887181699276, -0.1409899741411209, -0.02380816452205181, 0.13830716907978058, -0.010379873216152191, 0.025237374007701874, 0.26229190826416016, -0.03723067790269852, 0.020249366760253906, -0.03979208320379257, -0.01957094296813011, -0.2356836497783661, 0.04648452624678612, 0.06505654007196426, 0.059893712401390076, 1.4383291571311907e-32, 0.007280114572495222, 0.0518597736954689, 0.20316188037395477, -0.13096652925014496, -0.11404535919427872, 0.062309928238391876, -0.0026820325292646885, -0.03728635981678963, -0.1261470764875412, -0.2688913643360138, -0.11494644731283188, 0.11200840026140213, -0.06998269259929657, 0.05552985146641731, -0.21220605075359344, -0.12390084564685822, -0.16773730516433716, 0.1251867264509201, -0.07629384845495224, 0.00584067078307271, -0.02648683823645115, -0.001374601386487484, -0.018301883712410927, 0.14654237031936646, -0.009552937932312489, 0.09436807781457901, -0.06042076647281647, 0.06499098986387253, 0.064969003200531, 0.0979168713092804, -0.1739649474620819, 0.07468247413635254, 0.0626002699136734, -0.10926824063062668, -0.016472581773996353, 0.09292387962341309, -0.11710824072360992, -0.18929295241832733, -0.025367049500346184, 0.03350140154361725, -0.005520912818610668, -0.08545664697885513, -0.12373252213001251, -0.11187689006328583, 0.00437957001850009, -0.0005889635649509728, -0.18967440724372864, 0.009187390096485615, -0.010651377961039543, -0.1079287901520729, -0.07571429014205933, 0.13388343155384064, -0.2418280839920044, -0.005278921686112881, -0.061545513570308685, 0.003503271611407399, -0.03724763169884682, -0.045188698917627335, 0.15858188271522522, -0.04661453515291214, 0.2559959292411804, 0.028673360124230385, -0.0322832353413105, -0.05924883857369423, -0.14930173754692078, 0.038208652287721634, -0.11811406165361404, -0.21654869616031647, -0.15035559237003326, 0.09582613408565521, 0.02259037271142006, -0.01998303271830082, 0.041544944047927856, -0.06340352445840836, 0.19119398295879364, -0.06785444915294647, 0.05319226533174515, -0.018065916374325752, 0.061191752552986145, 0.09333968162536621, 0.001962163718417287, -0.18254026770591736, -0.01867283135652542, -0.0002360372745897621, 0.20968082547187805, -0.06805667281150818, -0.0862913727760315, 0.045417916029691696, -0.038753949105739594, -0.05999358370900154, 0.06935453414916992, 0.16278070211410522, -0.014698702841997147, 0.15309438109397888, -0.0934358686208725, -1.4971334089678695e-32, -0.07518351823091507, -0.0358131118118763, 0.1241297572851181, 0.0612163171172142, 0.02374996803700924, 0.11908461898565292, -0.007029358297586441, 0.05496938154101372, 0.23106712102890015, -0.0037832381203770638, 0.18718436360359192, -0.021995555609464645, -0.14216670393943787, -0.07533260434865952, 0.07795869559049606, 0.06343355774879456, -0.06510145962238312, -0.05553276464343071, -0.1636696308851242, 0.076410673558712, -0.01984923891723156, 0.10615044087171555, -0.051708344370126724, 0.23623840510845184, 0.08751540631055832, -0.015117228031158447, 0.0942096933722496, 0.08198267221450806, 0.13991722464561462, -0.01861146278679371, -0.20238277316093445, -0.0017505186842754483, -0.27979370951652527, 0.15206018090248108, -0.18515755236148834, -0.04409707337617874, 0.10736799985170364, -0.05573451146483421, 0.04012305289506912, -0.03391260281205177, 0.07440122216939926, -0.030224880203604698, -0.19177238643169403, -0.04131685197353363, -0.023759059607982635, 0.09768754988908768, 0.05232587084174156, 0.13776978850364685, 0.1132776066660881, 0.07177935540676117, -0.1064450815320015, 0.16541242599487305, 0.028702078387141228, 0.16041436791419983, -0.11673612147569656, 0.13349203765392303, -0.09148646891117096, -0.0033441432751715183, 0.0755900889635086, 0.03227680176496506, 0.05012150853872299, 0.20870272815227509, -0.20951974391937256, 0.023642675951123238, 0.20738951861858368, 0.13857612013816833, 0.053023628890514374, -0.030783984810113907, 0.03207401931285858, -0.09799569845199585, -0.05952663719654083, -0.04839201271533966, -0.13134895265102386, -0.1978536695241928, -0.019071321934461594, 0.05136532709002495, -0.0829763263463974, -0.10937139391899109, -0.2072119563817978, 0.10603796690702438, 0.06917672604322433, 0.004425508435815573, 0.1258104145526886, 0.04232623055577278, -0.05733494460582733, -0.027608297765254974, -0.05489160493016243, -0.15158642828464508, -0.02453538589179516, 0.09793572872877121, -0.1301824152469635, -0.05297720059752464, -0.1759447306394577, 0.22894760966300964, 0.09616261720657349, -1.0012176687723695e-07, 0.0027810600586235523, -0.05959020555019379, 0.11132563650608063, -0.03279871121048927, 0.2940690219402313, 0.002682759892195463, -0.19901494681835175, -0.00302926660515368, 0.038937706500291824, 0.1342422366142273, -0.07282395660877228, -0.009217769838869572, -0.04307129606604576, 0.06964113563299179, -0.0261455737054348, 0.1121261790394783, -0.054524581879377365, 0.025552665814757347, -0.028762036934494972, -0.06318576633930206, -0.0010729224886745214, -0.08332525938749313, 0.20800019800662994, 0.01670101471245289, -0.03208433464169502, 0.01862880401313305, 0.025877604261040688, 0.2591193616390228, 0.0618152841925621, -0.12360108643770218, -0.08753334730863571, 0.04174592345952988, 0.05697455629706383, 0.012449795380234718, -0.09481824189424515, 0.028254292905330658, 0.09231273829936981, 0.029934247955679893, 0.09635686874389648, 0.1088925153017044, 0.014985758811235428, -0.001882597804069519, 0.11516263335943222, 0.06253118067979813, -0.12292668223381042, 0.05279869958758354, -0.029205134138464928, -0.06164080277085304, -0.034161679446697235, -0.1016489714384079, 0.14686568081378937, -0.10173489153385162, 0.11099429428577423, -0.02646050788462162, -0.06455644220113754, 0.1143953874707222, 0.027200443670153618, -0.1777329444885254, 0.026133287698030472, -0.04210700839757919, 0.014242289587855339, -0.23147116601467133, 0.26788878440856934, 0.09455601125955582], "changes": {"1wk": -9.01492673959305, "1mo": -29.55223766725455}}, {"text": "Corbus Pharmaceuticals Holdings, Inc. (CRBP): An Oversold Healthcare Stock to Invest In Now Laiba Immad Tue, Nov 26, 2024, 2:54 PM 5 min read In This Article: CRBP -2.86% We recently compiled a list of the 10 Oversold Healthcare Stocks To Invest In . In this article, we are going to take a look at where Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) stands against the other oversold healthcare stocks. The Promising Outlook for Healthcare Investments in 2024 Investing in healthcare stocks during lean economic times is generally regarded as defensive. This is because people typically do not cut back on their use of prescription medications or other essential healthcare services, even during difficult financial times. According to the Centers for Medicare and Medicaid Services (CMS), national healthcare spending is projected to reach an estimated $4.8 trillion in 2023 and grow at an annual rate of 5.6% between 2027 and 2032. In the US, the healthcare sector is flourishing. According to a recent estimate, the country's healthcare spending increased by 7.5% in 2023, above the nominal GDP growth rate for the same year. A record 93.1% of Americans now have health insurance, which helped fuel last year's sharp increase in healthcare spending. The United States' national healthcare spending is expected to increase at an average rate of 5.6% between 2023 and 2032, above the 4.3% growth predicted for GDP. Additionally, the industry is growing quickly on a global scale. According to recent McKinsey projections, healthcare profits would increase at a compound annual growth rate (CAGR) of 7% from $583 billion in 2022 to over $800 billion by 2027. Although labor shortages and rising inflation rates continued to put pressure on the business in 2023, a good risk-reward climate in the sector is expected to make 2024 a year of recovery. According to the American investment firm, the events of 2023 have produced an alluring opportunity for investors to engage in the healthcare industry. Investments in AI within the healthcare sector have grown rapidly, outpacing the tech industry, with $2.8 billion invested in AI healthcare corporations in 2024, and over $11 billion expected by the end of the year. According to a Silicon Valley Bank report, one-quarter of healthcare spending now goes to AI-driven companies. Deloitte's 2024 Global Health Care Sector Outlook highlights high investor confidence, with $31.5 billion in private equity funding between 2019 and 2022. AI is expected to save $360 billion in U.S. healthcare over the next five years by improving patient care, diagnosis, treatment, and medical administration. Optimism in the healthcare industry is growing as 2024 goes on. Financial experts anticipate better earnings this year despite 2023's poor performance. The healthcare industry has a \"favorable risk-reward environment,\" according to BlackRock's 2024 prediction, which also notes that investors now have an appealing starting point because of last year's poor performance. In view of this, we will take a look at oversold stocks from the healthcare sector. Story Continues Our Methodology For our methodology, we used a stock screener and selected healthcare stocks that had an RSI below 30, mid-market cap, and high institutional ownership. Then we ranked the stocks based on their total number of hedge fund holders as of Insider Monkey\u2019s database of Q3 2024. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). A biopharmaceutical scientist in a lab examining a vial of pharmaceuticals. Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP ) Number of Hedge Fund Holders: 25 Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) is a clinical-stage biopharmaceutical company focused on developing therapies for oncology and fibrotic diseases. It specializes in precision oncology, with two key experimental drugs in its pipeline: CRB-701, an antibody-drug conjugate targeting Nectin-4 on cancer cells, and CRB-601, an anti-integrin monoclonal antibody that blocks TGF\u03b2 activation in cancer cells. Corbus generates revenue through partnerships, including a licensing agreement with CSPC Pharmaceutical Group for CRB-701, which includes upfront payments, milestones, and royalties. It is one of the best oversold stocks on our list. At the ASCO 2024 conference, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) reported promising results for CRB-701, showing an Overall Response Rate (ORR) of 44% in metastatic urothelial cancer and 43% in cervical cancer patients. The Disease Control Rate (DCR) was even higher, at 78% for bladder cancer and 86% for cervical cancer, indicating significant tumor shrinkage or stabilization. As of Q3 2024, 25 hedge funds in the Insider Monkey database held shares in Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), and out of these hedge fund holders, the largest stakeholder of the company was Cormorant Asset Management with shares worth $48.9 million. Street analysts hold a consensus Strong Buy rating on the stock. Analysts have given 12-month price targets for Corbus Pharmaceuticals, with an average target of $80.67, a high of $88.00, and a low of $73.00. This represents a 333.01% increase from the current price of $18.63. Overall CRBP ranks 9th on our list of the oversold healthcare stocks to invest in. While we acknowledge the potential of CRBP as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CRBP but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-11-26T14:54:26", "sentiment": {"score": 0.8900164477527142, "confidence": 0.9135566353797913, "probabilities": {"positive": 0.9135566353797913, "negative": 0.023540187627077103, "neutral": 0.06290309131145477}}, "embedding": [0.008983475156128407, -0.08876489847898483, -0.057455770671367645, -0.10061663389205933, 0.01062629371881485, 0.11252544820308685, -0.028402775526046753, 0.1204872876405716, 0.08452343940734863, 0.10129013657569885, -0.17887645959854126, 0.19592539966106415, -0.017377076670527458, -0.1311972439289093, -0.06376628577709198, 0.010201514698565006, 0.02158777043223381, -0.12796668708324432, -0.04244397580623627, 0.17466312646865845, -0.0412021167576313, 0.032336313277482986, 0.03597986325621605, -0.00706007145345211, -0.044294096529483795, -0.05093958601355553, 0.03780511021614075, -0.15820136666297913, -0.22978979349136353, 0.09663323312997818, 0.10982289910316467, 0.07899272441864014, 0.06147611886262894, 0.014525791630148888, -0.0744757354259491, 0.07159022986888885, 0.003844131948426366, 0.010916247963905334, 0.06666911393404007, 0.06185733899474144, -0.013209044001996517, -0.010541650466620922, -0.07519003003835678, 0.08703575283288956, 0.14435909688472748, -0.09441190958023071, -0.07332105934619904, 0.08087000250816345, 0.10358507186174393, 0.08443263173103333, -0.16098694503307343, -0.02396463230252266, 0.02668391354382038, 0.0624498650431633, -0.037890806794166565, 0.028424818068742752, -0.1108555942773819, -0.032908596098423004, 0.018244236707687378, 0.09060508012771606, -0.01846330054104328, 0.034633733332157135, 0.2914762794971466, 0.030987070873379707, 0.0990099161863327, 0.07047388702630997, 0.028706144541502, -0.013250024989247322, -0.14609745144844055, 0.11404941976070404, 0.04577670991420746, -0.13611647486686707, -0.06533655524253845, -0.14345957338809967, -0.04772600531578064, 0.040665462613105774, -0.002765871584415436, 0.15617844462394714, 0.1914612054824829, -0.12999476492404938, 0.11736440658569336, 0.03936777263879776, 0.0502435527741909, -0.07465428113937378, -0.07923395931720734, -0.019326101988554, 0.0028099436312913895, -0.01803019270300865, 0.06605060398578644, -0.05318779870867729, 0.0784546509385109, -0.11669737100601196, -0.03452116996049881, -0.0017105045262724161, 0.0541878379881382, 0.011330921202898026, -0.06113249063491821, 0.05551744997501373, -0.11231694370508194, -0.06914015114307404, 0.060460519045591354, 0.08694743365049362, 0.05985432118177414, -0.0652366578578949, -0.061652958393096924, -0.09591589868068695, 0.11475804448127747, 0.036620110273361206, 0.10809977352619171, 0.05317412316799164, -0.06110920384526253, 0.07614446431398392, -0.044584356248378754, -0.03758993372321129, 0.02213302254676819, 0.09135617315769196, 0.08559104800224304, -0.08352907747030258, 0.0866023600101471, 0.13622614741325378, 0.09878038614988327, 0.03896203264594078, -0.11653360724449158, -0.08286792784929276, -0.07246443629264832, -0.004619567655026913, -0.19922196865081787, 5.38389049240879e-33, 0.05639711767435074, 0.022953232750296593, 0.1493329107761383, -0.09736976027488708, -0.20453378558158875, -0.021489117294549942, 0.032997891306877136, -0.05478660389780998, -0.09601357579231262, -0.12509804964065552, -0.23019608855247498, 0.0961219072341919, -0.0741153284907341, 0.09670628607273102, 0.06531807780265808, -0.1927764117717743, -0.12132617086172104, 0.12812773883342743, 0.04077807441353798, -0.01047764252871275, -0.09777463972568512, -0.019260205328464508, -0.04225713759660721, 0.07488396763801575, 0.08641920983791351, 0.016174089163541794, -0.05200120061635971, -0.11198371648788452, 0.03953550383448601, 0.03741971030831337, 0.02121099643409252, 0.09499873220920563, -0.12294086813926697, -0.07658899575471878, -0.1154908537864685, -0.16463206708431244, -0.07939276099205017, 0.08468732982873917, -0.034780148416757584, -0.01713084615767002, -0.049579642713069916, 0.05949413776397705, -0.00014371133875101805, -0.00750622246414423, 0.037170879542827606, -0.01340281218290329, 0.03679890185594559, -0.020255204290151596, -0.14046937227249146, -0.1432318389415741, -0.1643417775630951, 0.08507158607244492, -0.043224867433309555, -0.000305885449051857, 0.0229793693870306, -0.09576806426048279, -0.047502242028713226, -0.1599043756723404, 0.022452864795923233, -0.002191603183746338, 0.05774223431944847, -0.013943212106823921, 0.005762645974755287, 0.018814004957675934, -0.14455653727054596, 0.217323899269104, 0.010284642688930035, 0.08350186049938202, -0.016764579340815544, 0.18248412013053894, 0.10998962819576263, -0.0477287694811821, -0.058956269174814224, -0.02206013724207878, 0.033157773315906525, 0.04519183933734894, 0.01733621209859848, -0.10213881731033325, 0.03431744500994682, 0.11422836780548096, -0.020054670050740242, -0.05813869461417198, 0.03545984998345375, -0.02103053778409958, 0.10491965711116791, -0.03075036033987999, 0.05173554643988609, 0.05042845755815506, -0.02368483878672123, -0.18692007660865784, -0.12911832332611084, 0.001967739313840866, 0.11545363068580627, 0.08607080578804016, -0.04163782671093941, -8.27775040325393e-33, -0.029332134872674942, 0.03621583431959152, 0.040833644568920135, -0.01551632210612297, 0.020989395678043365, -0.1152498871088028, 0.09699780493974686, -0.02341292053461075, 0.10663674771785736, -0.06310442090034485, 0.011411003768444061, 0.0008119326084852219, 0.06342612951993942, 0.10348783433437347, -0.06031492352485657, -0.01593230478465557, 0.00036492105573415756, -0.06565187871456146, 0.01059175655245781, -0.11293420195579529, 0.052794381976127625, 0.041839130222797394, 0.03703710436820984, 0.13636796176433563, 0.0019620656967163086, 0.1682092249393463, -0.1198539063334465, 0.04748160392045975, 0.1376773715019226, -0.10229471325874329, -0.13499900698661804, 0.04670131951570511, -0.131381094455719, 0.12180298566818237, -0.08768072724342346, 0.0006388360634446144, -0.02649589069187641, -0.13467325270175934, 0.02576250582933426, -0.11039519309997559, 0.2804013192653656, -0.05560927838087082, -0.11675196886062622, 0.006984159350395203, 0.10315409302711487, -0.08712105453014374, -0.015553763136267662, 0.10540136694908142, 0.1547951102256775, 0.009132753126323223, 0.009536085650324821, 0.029646236449480057, -0.041874341666698456, 0.13033998012542725, -0.14634215831756592, 0.1729978322982788, 0.03061266429722309, -0.06027672812342644, -0.1101110428571701, -0.03664456307888031, -0.06869897246360779, 0.15819896757602692, -0.045663852244615555, -0.04652094841003418, -0.050773970782756805, -0.013120785355567932, 0.12357653677463531, -0.01525529008358717, 0.07940748333930969, -0.23677654564380646, 0.07743879407644272, -0.10479426383972168, -0.06895343959331512, -0.0595695823431015, -0.015170508064329624, 0.16703961789608002, 0.02374635823071003, -0.07440316677093506, -0.046524036675691605, 0.11588739603757858, 0.04911057651042938, -0.1499854326248169, 0.06974174082279205, -0.0993196964263916, -0.16769827902317047, 0.06882679462432861, 0.019152894616127014, -0.15596888959407806, -0.22435614466667175, 0.11321569979190826, -0.25782525539398193, -0.05366251617670059, -0.1715279221534729, 0.04263199865818024, -0.06922155618667603, -9.986666782424436e-08, 0.10237440466880798, 0.0795086920261383, 0.1931402087211609, -0.0803447961807251, 0.14900365471839905, -0.17925696074962616, -0.058746807277202606, 0.05342935770750046, 0.0843675434589386, 0.14973369240760803, 0.09160655736923218, 0.10051882266998291, -0.010139577090740204, 0.028960715979337692, -0.13904063403606415, 0.1518530249595642, -0.20897074043750763, 0.03490946814417839, -0.01556111965328455, -0.07662606984376907, 0.017997341230511665, -0.016463886946439743, 0.06094604358077049, 0.03170859441161156, -0.0720575675368309, 0.10725146532058716, -0.1019144058227539, -0.02856980636715889, -0.029778271913528442, 0.17833301424980164, -0.04019147530198097, 0.013127405196428299, 0.12198133766651154, 0.036547090858221054, -0.070560023188591, -0.2025458812713623, 0.07321841269731522, -0.04951581358909607, 0.06766682863235474, -0.0194915309548378, 0.0534893274307251, 0.08020874857902527, 0.06601099669933319, -0.005364606156945229, 0.06404198706150055, -0.23083724081516266, -0.025979258120059967, 0.05254416912794113, 0.018856342881917953, -0.14927880465984344, 0.04646666347980499, 0.03820125386118889, 0.03308640047907829, 0.07131624966859818, 0.06933510303497314, 0.09043748676776886, -0.09947986155748367, -0.035464368760585785, -0.21437281370162964, -0.0015522520989179611, -0.05105186253786087, -0.2663347125053406, 0.1581088751554489, 0.1198098212480545], "changes": {"1wk": -0.7786395618062656, "1mo": -26.751944318148308}}, {"text": "Corbus Pharmaceuticals Announces Dosing of First Patient in its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors Corbus Pharmaceuticals Holdings, Inc. Mon, Dec 9, 2024, 3:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. CRB-601 is an anti-\u03b1v\u03b28 monoclonal antibody designed to block activation of latent TGF\u03b2 in the tumor micro-environment NORWOOD, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an oncology and obesity company with a diversified portfolio, today announced the dosing of the first patient in the \u00a0Phase 1 portion of the clinical study of CRB-601 for the treatment of patients with advanced solid tumors ( NCT06603844 ). CRB-601 is a monoclonal antibody targeting latent TGF\u03b2 activation-by blocking the integrin \u03b1V\u03b28. Pre-clinical data has demonstrated that CRB-601 overcomes tumor immune exclusion and enhances the activity of immune checkpoint inhibitors in vivo . \u201cCRB-601 offers an intriguing upstream approach to modulating TGF\u03b2 signaling and this dose escalation study could yield valuable insights along with the potential to see the immune system being mobilized and the prospect of tumors responding.\u201d said Dr. Dominic Smethurst, MA, MRCP, Chief Medical Officer of Corbus.\u201d \u201cDosing CRB-601 in a clinical trial marks an important milestone, bringing us closer to understanding its potential in the clinic and paving the way for advancements in an exciting corner of immunotherapy,\" said Dr. Jeffrey M. Clarke, MD., Associate Professor of Medicine, Associate Director of Thoracic Oncology Clinical Research Program, Duke Cancer Institute, Raleigh, NC. and a principal investigator in the CRB-601 study. About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on Facebook , LinkedIn and X . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's restructuring, trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Story Continues These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals smoran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-12-09T15:00:00", "sentiment": {"score": 0.6788662131875753, "confidence": 0.6875620484352112, "probabilities": {"positive": 0.6875620484352112, "negative": 0.008695835247635841, "neutral": 0.303741991519928}}, "embedding": [-0.11498312652111053, -0.05546628683805466, -0.08233480900526047, -0.1534208506345749, 0.011242943815886974, -0.03381693363189697, 0.016623545438051224, 0.14826366305351257, 0.07410451769828796, -0.012415376491844654, -0.15764854848384857, -0.022042755037546158, 0.06090187281370163, 0.020544111728668213, -0.07357904314994812, 0.14692258834838867, 0.06475797295570374, -0.05321851000189781, 0.01625225320458412, -0.03869534283876419, -0.16065417230129242, -0.025722529739141464, -0.07494296133518219, 0.15333060920238495, -0.05826900154352188, -0.08096016943454742, -0.11118653416633606, -0.006978314369916916, -0.24502485990524292, 0.06248337775468826, 0.04529133439064026, 0.06280772387981415, -0.0889304131269455, -0.010426785796880722, -0.09580463171005249, -0.011178717017173767, -0.1454964429140091, 0.026218442246317863, -0.08775091171264648, -0.06915570795536041, -0.0457012876868248, 0.03812295198440552, -0.052039097994565964, 0.11099384725093842, 0.05790533125400543, -0.3149937391281128, -0.16833283007144928, 0.0884123295545578, 0.07961137592792511, 0.12123548984527588, -0.05142197757959366, -0.04870188981294632, -0.1710122525691986, 0.321811705827713, 0.008514001034200191, 0.1254902184009552, -0.22714850306510925, 0.06344825774431229, 0.15625835955142975, -0.023468298837542534, -0.15293559432029724, -0.06931495666503906, 0.26467013359069824, 0.08085928112268448, 0.15889710187911987, -0.02409471943974495, -0.0924491211771965, -0.03221777081489563, -0.11307921260595322, 0.06325270235538483, 0.09341193735599518, 0.0027819485403597355, -0.08886295557022095, 0.08230140805244446, -0.010701273567974567, 0.08736353367567062, 0.0013757813721895218, 0.14383892714977264, 0.15778017044067383, -0.07540518790483475, -0.06209792569279671, 0.15512770414352417, 0.20265571773052216, -0.049459364265203476, -0.09416066110134125, -0.021651867777109146, 0.033014144748449326, 0.10316681116819382, 0.0931423008441925, 0.04158823937177658, 0.21709689497947693, 0.09374982118606567, 0.018258903175592422, 0.10337190330028534, 0.015922466292977333, -0.05913497135043144, -0.09283362329006195, 0.033146049827337265, -0.022978108376264572, -0.03657764568924904, -0.051539041101932526, 0.0762067511677742, -0.04287703335285187, -0.09433300793170929, 0.029058154672384262, -0.057667165994644165, 0.04591026157140732, 0.16379646956920624, -0.009500108659267426, 0.0491943322122097, -0.023871997371315956, 0.03908500820398331, 0.052057649940252304, -0.001737823709845543, 0.0956883579492569, 0.18875837326049805, -0.02609924226999283, -0.008746866136789322, 0.170881450176239, -0.1121147945523262, 0.06402163952589035, -0.034833431243896484, -0.020427847281098366, -0.18140742182731628, 0.057191383093595505, 0.22476094961166382, -0.07973668724298477, 7.558750467365846e-33, 0.04899986833333969, -0.06602630019187927, 0.16769009828567505, 0.14182624220848083, -0.08862289786338806, -0.10232394188642502, 0.03686648607254028, 0.05353540554642677, -0.17569805681705475, -0.12706102430820465, -0.09805390238761902, 0.03467458114027977, 0.003916146233677864, 0.14963427186012268, -0.14028066396713257, -0.152557834982872, -0.00893370434641838, -0.002719396725296974, -0.03386950120329857, -0.05609288066625595, -0.0995662584900856, 0.12863174080848694, -0.07521595060825348, 0.0208071768283844, -0.01198488101363182, 0.01946130022406578, -0.05912330374121666, 0.17769522964954376, -0.02075936459004879, 0.0641292855143547, -0.19629791378974915, 0.13929641246795654, -0.036139991134405136, -0.060086168348789215, -0.06422030180692673, -0.07836592942476273, -0.06744208931922913, -0.1660604178905487, -0.12145312130451202, 0.051668599247932434, 0.14990796148777008, -0.03612956404685974, -0.14179733395576477, -0.16023419797420502, 0.09936127066612244, -0.084624283015728, -0.022791273891925812, -0.004882459994405508, -0.12855447828769684, -0.012130079790949821, 0.03905549645423889, 0.06040637195110321, -0.04007274657487869, 0.03174121305346489, -0.09163832664489746, -0.013825228437781334, -0.1572711169719696, -0.05249955132603645, 0.20751766860485077, 0.015069592744112015, 0.018232811242341995, -0.07963414490222931, 0.004368927329778671, 0.12558740377426147, 0.021039264276623726, 0.0696987435221672, -0.10980997234582901, -0.130174458026886, -0.06165304780006409, 0.05565398558974266, 0.03150247409939766, -0.06985674798488617, 0.1755816638469696, -0.007936853915452957, 0.15873116254806519, -0.047117672860622406, 0.16359874606132507, 0.032941609621047974, -0.11124837398529053, 0.11356358230113983, 0.05596526712179184, -0.05950823426246643, -0.11464472860097885, 0.06042398512363434, 0.05732836574316025, -0.21419881284236908, -0.006693462375551462, -0.08090907335281372, -0.11029621958732605, -0.06674358993768692, 0.07337286323308945, -0.03258796036243439, -0.056170232594013214, 0.21632274985313416, -0.13689354062080383, -7.138900619450588e-33, -0.04506887495517731, -0.1622442603111267, 0.06349973380565643, -0.025820009410381317, 0.011778609827160835, 0.12659701704978943, 0.2352578341960907, -0.27640390396118164, 0.16558031737804413, -0.17571207880973816, 0.05099564418196678, 0.01793738082051277, -0.13211679458618164, -0.08798352628946304, -0.06411679089069366, -0.029718872159719467, 0.0036077555269002914, -0.014050940051674843, -0.14610344171524048, 0.05642694979906082, 0.008466659113764763, 0.13164380192756653, -0.07350380718708038, 0.059992190450429916, -0.03596237301826477, 0.11776944994926453, 0.06313086301088333, 0.08035227656364441, 0.03528948500752449, 0.013468872755765915, -0.015820447355508804, 0.07335418462753296, -0.1159941703081131, 0.11255486309528351, -0.12308929860591888, -0.04762173444032669, 0.13211244344711304, -0.1894702911376953, 0.09742209315299988, -0.12084530293941498, 0.06076078489422798, 0.0007331972010433674, -0.11918159574270248, -0.005041065625846386, -0.014598893001675606, 0.11095278710126877, 0.14590789377689362, 0.15057840943336487, 0.08724161237478256, 0.007379109971225262, -0.024004817008972168, -0.006943890359252691, 0.04308253526687622, 0.014300868846476078, 0.012521938420832157, 0.06190738454461098, -0.052378732711076736, -0.05825606733560562, 0.12549085915088654, 0.03580019995570183, 0.036093201488256454, 0.1366017609834671, 0.08432494103908539, -0.005228586494922638, 0.09711076319217682, 0.24811390042304993, 0.07770673930644989, 0.06933687627315521, -0.011069581843912601, -0.11815924942493439, -0.039358798414468765, -0.013179030269384384, -0.009960473515093327, -0.08199808746576309, 0.09377984702587128, 0.045747317373752594, 0.04083315283060074, -0.1170232892036438, -0.13542070984840393, 0.033981554210186005, -0.10849982500076294, -0.14074885845184326, 0.005587139632552862, -0.018767213448882103, 0.00531124509871006, 0.0633835420012474, -0.10853943228721619, -0.052607711404561996, -0.019940892234444618, 0.10247792303562164, -0.10132507979869843, -0.07990799844264984, -0.0631193146109581, 0.17356203496456146, 0.04767956957221031, -9.952521651257484e-08, 0.12088850140571594, -6.789510371163487e-05, 0.07773555815219879, -0.1564033031463623, 0.09551018476486206, 0.004171586595475674, -0.03303395211696625, -0.04283245652914047, -0.0441698282957077, 0.13252101838588715, 0.02818480134010315, -0.001971743069589138, -0.0340857058763504, 0.003079869318753481, -0.10009583085775375, 0.07356758415699005, -0.05806489288806915, -0.11021789908409119, -0.09063857793807983, -0.012990026734769344, -0.04911252111196518, -0.04679899290204048, 0.17744159698486328, 0.06841093301773071, 0.09601673483848572, -0.16233666241168976, -0.0008975360542535782, 0.19929161667823792, 0.03399072587490082, -0.00019467715173959732, -0.12951280176639557, 0.08206925541162491, 0.006740851327776909, 0.04331405833363533, 0.0650223046541214, 0.026143718510866165, 0.15227609872817993, -0.003239142242819071, 0.03215041756629944, 0.11171694099903107, 0.019941868260502815, -0.029765525832772255, 0.027354644611477852, -0.11978594958782196, -0.045165371149778366, -0.03364025056362152, -0.09652179479598999, 0.11589404940605164, -0.14806607365608215, -0.08130890876054764, -0.016737716272473335, 0.04246414452791214, -0.09644706547260284, 0.04199380427598953, -0.01290622167289257, 0.09363599866628647, -0.09069614857435226, -0.14048586785793304, 0.12081116437911987, -0.11246725171804428, 0.03540530055761337, -0.0697585865855217, 0.15347892045974731, -0.03710305318236351], "changes": {"1wk": -1.0498677809387533, "1mo": -17.322830900900595}}, {"text": "FDA Grants Fast Track Designation to CRB-701 for the Treatment of Relapsed or Refractory Metastatic Cervical Cancer Corbus Pharmaceuticals Holdings, Inc. Tue, Dec 3, 2024, 3:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. NORWOOD, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an oncology and obesity company with a diversified portfolio, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CRB-701 for the treatment of relapsed or refractory metastatic cervical cancer. CRB-701 (SYS6002) is a next-generation antibody drug conjugate (ADC) targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. The FDA\u2019s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions that demonstrate the potential to fill an unmet medical need. Corbus recently completed enrollment of the dose escalation part of its Phase 1 clinical trial of CRB-701 (SYS6002) ( NCT06265727 ) that is being conducted in the U.S. and Europe. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high Nectin-4 expression. The Company expects to report the first data from the dose escalation clinical study in Q1 2025. About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on X , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. Story Continues These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals smoran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-12-03T15:00:00", "sentiment": {"score": 0.35559680592268705, "confidence": 0.3632146418094635, "probabilities": {"positive": 0.3632146418094635, "negative": 0.007617835886776447, "neutral": 0.6291674375534058}}, "embedding": [-0.07288867980241776, -0.12612858414649963, -0.13538266718387604, -0.1674414575099945, 0.0004124866100028157, -0.0384860560297966, -0.15010088682174683, 0.21213331818580627, 0.021800437942147255, 0.03354668244719505, -0.11162512004375458, -0.030760686844587326, 0.037380415946245193, 0.03690655156970024, -0.053478434681892395, 0.019118359312415123, 0.07498177886009216, -0.025412216782569885, 0.030832190066576004, 0.0018350337632000446, -0.05691492184996605, 0.033196572214365005, -0.04631742835044861, 0.06786806881427765, -0.07919155806303024, -0.23081538081169128, -0.1773848533630371, 0.019771862775087357, -0.18233928084373474, 0.036355480551719666, 0.16227108240127563, 0.09044405817985535, -0.176608145236969, -0.020609814673662186, 0.0055726058781147, -0.06378652155399323, -0.10717865824699402, -0.07623566687107086, -0.040956590324640274, -0.01404600590467453, 0.018285080790519714, 9.185262024402618e-05, -0.07190002501010895, 0.11494535207748413, 0.07632191479206085, -0.22566838562488556, -0.22607386112213135, 0.09477043151855469, 0.10258109122514725, 0.12328127026557922, -0.04296506941318512, -0.06370136141777039, -0.21479010581970215, 0.3553984761238098, 0.010913347825407982, 0.08481638133525848, -0.19343118369579315, 0.01352988462895155, 0.14884208142757416, 0.035305723547935486, -0.10114789009094238, -0.08346057683229446, 0.20818600058555603, 0.07339388132095337, 0.08194352686405182, 0.009645747020840645, -0.09284936636686325, -0.08349170535802841, -0.07853810489177704, 0.0677420049905777, 0.10586285591125488, -0.06763134896755219, -0.0781552791595459, 0.1074180006980896, -0.01004568301141262, 0.09372551739215851, -0.008354134857654572, 0.1864672750234604, 0.06364546716213226, -0.18899595737457275, 0.054361894726753235, 0.12478882074356079, 0.16728892922401428, -0.040272004902362823, -0.00027919188141822815, -0.026411740109324455, 0.016377858817577362, 0.11432874202728271, 0.10318438708782196, 0.02829739637672901, 0.2856242060661316, 0.08325569331645966, 0.04871632531285286, 0.08494671434164047, -0.020578427240252495, -0.04062877222895622, -0.07929999381303787, 0.0748223289847374, -0.07608669996261597, -0.009194931015372276, -0.05441943183541298, 0.087381511926651, -0.13669808208942413, -0.1179603785276413, 0.037466730922460556, -0.06222808361053467, 0.03404150903224945, 0.1846436858177185, -0.07255862653255463, 0.0502936989068985, -0.01142713613808155, 0.03972676023840904, 0.09628833085298538, -0.08644698560237885, 0.012226530350744724, 0.18413862586021423, -0.008096624165773392, -0.061209000647068024, 0.2447742223739624, -0.08131071925163269, 0.04137080907821655, -0.022197000682353973, 0.041119903326034546, -0.21003951132297516, 0.1610228568315506, 0.15759900212287903, -0.08293873071670532, 8.523373621278093e-33, -0.03940357640385628, -0.060210153460502625, 0.20593714714050293, 0.03260665014386177, -0.09853804856538773, -0.04378902167081833, -0.014073100872337818, 0.03581063076853752, -0.14439186453819275, -0.1874423623085022, -0.10622991621494293, 0.039275575429201126, -0.032513804733753204, 0.08096528053283691, -0.11188782006502151, -0.17332467436790466, -0.03840120881795883, 0.042697515338659286, -0.14406754076480865, -0.08027227967977524, -0.05960649624466896, 0.07759755104780197, -0.07514305412769318, 0.08400222659111023, -0.0003859633579850197, 0.03822510316967964, -0.13332021236419678, 0.15009665489196777, 0.006429469212889671, 0.06356848776340485, -0.13741850852966309, 0.02261319011449814, 0.004035615362226963, -0.11264756321907043, -0.10723882913589478, -0.04862883314490318, -0.0973147600889206, -0.17416098713874817, -0.08563544601202011, 0.16334763169288635, 0.1091512143611908, -0.012555702589452267, -0.05541373789310455, -0.1306346356868744, 0.0931159108877182, -0.0918835699558258, -0.10305037349462509, 0.0690453052520752, -0.07269222289323807, 0.027111977338790894, 0.03067081980407238, 0.007878669537603855, -0.09609674662351608, -0.03663930296897888, -0.09217462688684464, 0.007076618727296591, -0.10961281508207321, -0.06166702136397362, 0.19989100098609924, 0.033088598400354385, 0.06359319388866425, -0.06984609365463257, -0.11384592950344086, 0.11421644687652588, -0.03063272312283516, 0.06383652985095978, -0.1051957905292511, -0.15255166590213776, -0.08429364860057831, 0.07739956676959991, -0.0769743099808693, -0.04727029800415039, 0.20677080750465393, 0.006779867224395275, 0.2308133989572525, -0.06615045666694641, 0.1382749378681183, -0.003134487196803093, -0.12043808400630951, 0.05468688905239105, -0.04246540367603302, -0.011802658438682556, -0.18131208419799805, 0.11904816329479218, 0.12624159455299377, -0.2506982684135437, -0.05538138374686241, -0.047287072986364365, -0.08951587229967117, -0.08510191738605499, 0.10493430495262146, 0.027238786220550537, -0.14462774991989136, 0.16134360432624817, -0.0538124218583107, -7.084268784812153e-33, -0.04685217887163162, -0.028790006414055824, 0.13987725973129272, 0.04876874387264252, 0.018334105610847473, 0.2008706033229828, 0.18415114283561707, -0.17992109060287476, 0.17244897782802582, -0.2002023458480835, 0.12259925901889801, -0.048823483288288116, -0.08179295063018799, -0.0837642103433609, -0.038229238241910934, 0.06189306825399399, -0.1289122998714447, 0.004781512543559074, -0.11730308830738068, 0.11799824237823486, 0.06252831965684891, 0.13055419921875, -0.048463378101587296, 0.06797502934932709, 0.0186007022857666, 0.06046922877430916, 0.11111559718847275, 0.0294504277408123, 0.11225035786628723, 0.03340006619691849, -0.055803049355745316, 0.020076077431440353, -0.21029913425445557, 0.17499282956123352, -0.14035338163375854, -0.05705661326646805, 0.11101710051298141, -0.206003338098526, -0.009184300899505615, -0.09506124258041382, 0.055215850472450256, 0.07002097368240356, -0.09716583043336868, -0.036559395492076874, -0.08841156959533691, 0.07238908857107162, 0.12723809480667114, 0.12129582464694977, 0.09321840852499008, 0.026352595537900925, -0.0037339460104703903, 0.0002813376486301422, 0.02318902313709259, 0.10901255905628204, -0.015702582895755768, 0.10151969641447067, -0.1041642352938652, -0.08964000642299652, 0.02082369290292263, 0.019248010590672493, 0.06778866052627563, 0.13276469707489014, 0.0715823620557785, -0.018950186669826508, 0.22467248141765594, 0.19228389859199524, 0.06553085148334503, 0.07421736419200897, -0.02079635299742222, -0.1529483199119568, -0.09035250544548035, -0.003727072849869728, -0.01032574288547039, -0.10548844933509827, 0.058407098054885864, 0.000781976617872715, -0.03086629882454872, -0.1583702713251114, -0.18667234480381012, 0.038616735488176346, -0.07904591411352158, -0.08517412096261978, 0.021908821538090706, 0.05213627591729164, 0.009634818881750107, 0.10189208388328552, -0.11343663930892944, -0.0007704365998506546, 0.06782108545303345, 0.10580073297023773, -0.09009885787963867, -0.014890340156853199, -0.005598769523203373, 0.2664424479007721, 0.028962738811969757, -9.934444022974276e-08, 0.03903161361813545, 0.004077923484146595, 0.08054257929325104, -0.12188825011253357, 0.152257040143013, 0.018234793096780777, -0.10519759356975555, -0.07323115319013596, -0.07569468766450882, 0.17078366875648499, 0.04455552250146866, 0.08296217769384384, -0.09172768145799637, 0.02360599860548973, -0.12344467639923096, 0.1319975107908249, -0.05334910750389099, -0.0590461865067482, -0.046966858208179474, 0.03420766815543175, -0.11263614892959595, -0.022275282070040703, 0.1004045158624649, 0.05956247076392174, 0.05976487696170807, -0.08052137494087219, 0.05865117162466049, 0.2667090892791748, 0.082490935921669, -0.038172196596860886, -0.07712377607822418, 0.012843487784266472, 0.0710589736700058, -0.007776339538395405, -0.09604433178901672, -0.0237920880317688, 0.03865189850330353, 0.07845133543014526, 0.06999602168798447, 0.1617112010717392, 0.08286169171333313, 0.010954477824270725, 0.08238373696804047, -0.046869900077581406, -0.02730819396674633, -0.037257641553878784, -0.09411617368459702, 0.12062303721904755, -0.1050165593624115, -0.0498262494802475, -0.04148928448557854, -0.006665435619652271, -0.07434497028589249, -0.04568031430244446, -0.022576725110411644, 0.09272855520248413, -0.10653069615364075, -0.09650835394859314, 0.12281499803066254, -0.0986199751496315, 0.07158523797988892, -0.05222809314727783, 0.20721164345741272, 0.08409089595079422], "changes": {"1wk": -9.01492673959305, "1mo": -29.55223766725455}}, {"text": "We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate editorial-team@simplywallst.com (Simply Wall St) Sat, Nov 9, 2024, 5:39 PM 4 min read In This Article: CRBP -2.86% We can readily understand why investors are attracted to unprofitable companies. Indeed, Corbus Pharmaceuticals Holdings ( NASDAQ:CRBP ) stock is up 478% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So notwithstanding the buoyant share price, we think it's well worth asking whether Corbus Pharmaceuticals Holdings' cash burn is too risky. For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). Let's start with an examination of the business' cash, relative to its cash burn. See our latest analysis for Corbus Pharmaceuticals Holdings How Long Is Corbus Pharmaceuticals Holdings' Cash Runway? A cash runway is defined as the length of time it would take a company to run out of money if it kept spending at its current rate of cash burn. As at September 2024, Corbus Pharmaceuticals Holdings had cash of US$159m and no debt. In the last year, its cash burn was US$30m. So it had a cash runway of about 5.3 years from September 2024. While this is only one measure of its cash burn situation, it certainly gives us the impression that holders have nothing to worry about. Depicted below, you can see how its cash holdings have changed over time. NasdaqCM:CRBP Debt to Equity History November 9th 2024 How Is Corbus Pharmaceuticals Holdings' Cash Burn Changing Over Time? Corbus Pharmaceuticals Holdings didn't record any revenue over the last year, indicating that it's an early stage company still developing its business. Nonetheless, we can still examine its cash burn trajectory as part of our assessment of its cash burn situation. With cash burn dropping by 20% it seems management feel the company is spending enough to advance its business plans at an appropriate pace. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company . How Hard Would It Be For Corbus Pharmaceuticals Holdings To Raise More Cash For Growth? While Corbus Pharmaceuticals Holdings is showing a solid reduction in its cash burn, it's still worth considering how easily it could raise more cash, even just to fuel faster growth. Issuing new shares, or taking on debt, are the most common ways for a listed company to raise more money for its business. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. By looking at a company's cash burn relative to its market capitalisation, we gain insight on how much shareholders would be diluted if the company needed to raise enough cash to cover another year's cash burn. Story Continues Corbus Pharmaceuticals Holdings has a market capitalisation of US$223m and burnt through US$30m last year, which is 13% of the company's market value. Given that situation, it's fair to say the company wouldn't have much trouble raising more cash for growth, but shareholders would be somewhat diluted. Is Corbus Pharmaceuticals Holdings' Cash Burn A Worry? As you can probably tell by now, we're not too worried about Corbus Pharmaceuticals Holdings' cash burn. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Its weak point is its cash burn reduction, but even that wasn't too bad! Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. Separately, we looked at different risks affecting the company and spotted 5 warning signs for Corbus Pharmaceuticals Holdings (of which 4 don't sit too well with us!) you should know about. Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts) Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-11-09T17:39:05", "sentiment": {"score": 0.13744058646261692, "confidence": 0.1639629751443863, "probabilities": {"positive": 0.1639629751443863, "negative": 0.02652238868176937, "neutral": 0.809514582157135}}, "embedding": [0.0037573822773993015, -0.049423713237047195, 0.013081802986562252, -0.1094655692577362, 0.09223034232854843, -0.013523207046091557, 0.04883912205696106, 0.057751208543777466, 0.13732708990573883, 0.10344113409519196, -0.07542982697486877, 0.04180599004030228, -0.016477880999445915, -0.0444975346326828, -0.09855227172374725, -0.11377471685409546, -0.039046380668878555, -0.1230413019657135, -0.04750806838274002, 0.09738515317440033, -0.021861186251044273, -0.06193239614367485, 0.013082919642329216, 0.11880914866924286, -0.004655397497117519, -0.026188334450125694, -0.014975588768720627, 0.0012088059447705746, -0.17905867099761963, -0.03961317241191864, 0.07774814963340759, 0.1703433394432068, 0.051214445382356644, -0.014026987366378307, 0.007498383056372404, 0.05001916363835335, -0.050807543098926544, 0.09575894474983215, 0.07749131321907043, 0.12035481631755829, -0.09943613409996033, 0.0015804492868483067, -0.02586439624428749, 0.015940897166728973, 0.009848050773143768, -0.21802496910095215, 0.01930873468518257, 0.005677307490259409, -0.02325589209794998, 0.10153698921203613, -0.03712594881653786, 0.016142696142196655, -0.035201046615839005, 0.05962812155485153, -0.026555223390460014, 0.11255192756652832, -0.05982659012079239, -0.01947307586669922, -0.004207705147564411, -0.060531146824359894, 0.03544667363166809, 0.060301393270492554, 0.126105397939682, -0.008041925728321075, 0.07839871942996979, 0.037058137357234955, 0.1207156851887703, 0.02386586368083954, -0.031182490289211273, 0.08312219381332397, 0.15595850348472595, -0.02782137133181095, -0.09806299954652786, -0.11949276179075241, -0.1664355844259262, 0.11072374880313873, 0.03277961164712906, 0.15610870718955994, 0.08715756982564926, -0.1337341070175171, 0.0831863135099411, 0.021434975787997246, 0.038367681205272675, -0.1227516308426857, -0.12386088073253632, 0.015249310992658138, 0.15388593077659607, -0.10813642293214798, 0.10641659051179886, 0.0560491681098938, 0.10136105120182037, 0.02690298482775688, 0.05087021738290787, 0.03795533627271652, -0.07029970735311508, -0.0037493733689188957, -0.01254364289343357, 0.08734846860170364, -0.012461965903639793, -0.06576881557703018, 0.10204394161701202, 0.1631685197353363, -0.11074559390544891, -0.13004767894744873, 0.04531187191605568, -0.09087050706148148, 0.10017461329698563, 0.011694752611219883, 0.02492697536945343, 0.03915700316429138, -0.11748556792736053, 0.17069530487060547, -0.08676937222480774, -0.11948450654745102, 0.07658776640892029, 0.059484586119651794, -0.12720029056072235, -0.08375534415245056, 0.01787274330854416, -0.05766358971595764, 0.12553945183753967, 0.11085624992847443, -0.04246238246560097, -0.1042926013469696, -0.030179036781191826, -0.050057996064424515, -0.04836716875433922, 1.3635546390442404e-32, 0.020752202719449997, 0.026662109419703484, 0.07597866654396057, -0.06643134355545044, -0.08275766670703888, -0.027289506047964096, -0.048041243106126785, 0.029758363962173462, -0.10185156762599945, -0.03718995302915573, -0.08361846208572388, 0.043296411633491516, -0.03500073403120041, -0.04866597801446915, 0.0025336877442896366, -0.03841782733798027, -0.12866637110710144, -0.05324322357773781, 0.09513193368911743, -0.16564208269119263, -0.15134002268314362, 0.08657436072826385, -0.061056192964315414, 0.023449143394827843, 0.023064596578478813, -0.019842717796564102, -0.08692626655101776, 0.025939203798770905, -0.08018053323030472, 0.06251375377178192, -0.016315065324306488, 0.08926916122436523, -0.102307990193367, -0.11522069573402405, -0.05015277862548828, -0.02902611345052719, -0.113959401845932, -0.041906990110874176, 0.029394736513495445, -0.01557974237948656, -0.051218245178461075, 0.01586342789232731, -0.02966652810573578, -0.04586520791053772, 0.014270611107349396, 0.05119714140892029, -0.04028883948922157, 0.033414002507925034, -0.10257572680711746, -0.05156265199184418, 0.01480660866945982, 0.05609380453824997, 0.0749407708644867, 0.06847810000181198, -0.02698575146496296, -0.011172225698828697, 0.010805044323205948, -0.1539374589920044, 0.08607643842697144, 0.11915018409490585, 0.09785217046737671, 0.09705641120672226, -0.07231946289539337, 0.061612263321876526, -0.2565687894821167, 0.26559099555015564, -0.0016616699285805225, -0.027524426579475403, -4.8783840611577034e-05, 0.004615251440554857, 0.020512308925390244, -0.08132082223892212, 0.02846493385732174, -0.027310969308018684, 0.02180282399058342, -0.052806317806243896, 0.05435074120759964, 0.011851468123495579, -0.025393540039658546, 0.09507621079683304, -0.03778516873717308, -0.14520001411437988, 0.12004206329584122, -0.06570266932249069, 0.02507084235548973, -0.1427091360092163, 0.12039268761873245, -0.053380802273750305, -0.07940931618213654, 0.10685419291257858, -0.05310022085905075, -0.03422188758850098, 0.032477036118507385, 0.17032751441001892, -0.011590727604925632, -1.1774376633893875e-32, -0.002889503724873066, -0.001579062081873417, 0.0018309555016458035, 0.012526396661996841, -0.04352003335952759, -0.048006221652030945, 0.15420924127101898, -0.038024649024009705, -0.006010621786117554, -0.1364762932062149, -0.10080492496490479, -0.0506177619099617, -0.1681443452835083, 0.08587148785591125, -0.0011023232946172357, 0.04550127685070038, 0.13573512434959412, -0.05034825578331947, -0.08680567890405655, -0.07398610562086105, 0.03509983420372009, 0.09649750590324402, -0.0764804482460022, 0.049648478627204895, -0.08438272029161453, 0.11064091324806213, -0.05190037190914154, 0.00012443214654922485, -0.01819147914648056, -0.02777046710252762, -0.007259664591401815, 0.028399663046002388, -0.187484011054039, 0.07171033322811127, -0.04450323060154915, -0.11536717414855957, 0.005576517432928085, -0.10897938907146454, 0.019268536940217018, -0.09702769666910172, 0.0969739630818367, 0.10116979479789734, -0.022678202018141747, 0.004574202001094818, 0.08606190234422684, -0.07175587862730026, 0.025686554610729218, -0.0058942632749676704, 0.22148911654949188, 0.1897067278623581, 0.09706538915634155, -0.03154154494404793, -0.01758253574371338, 0.1540166139602661, -0.027178330346941948, 0.15729835629463196, -0.00026890821754932404, -0.05358188599348068, 0.010660983622074127, 0.034289486706256866, 0.006003830581903458, 0.10006265342235565, -0.03790498524904251, 0.03330967575311661, 0.015325192362070084, 0.01212102361023426, 0.02487274259328842, -0.010843640193343163, 0.002139523159712553, -0.10007418692111969, -0.0052014682441949844, -0.04877038300037384, -0.022151488810777664, 0.0179329514503479, -0.019283384084701538, 0.28317609429359436, -0.07761865109205246, -0.10063399374485016, -0.09991318732500076, 0.02890673652291298, -0.02881089225411415, -0.03989353030920029, 0.09623819589614868, 0.04758498817682266, -0.12804795801639557, 0.07523109018802643, -0.05203187093138695, -0.2073555290699005, -0.04996076971292496, 0.028769493103027344, -0.018735283985733986, -0.2304266095161438, -0.06984146684408188, 0.04248940199613571, 0.0646498054265976, -9.972761461085611e-08, -0.05164235085248947, -0.002023420063778758, 0.10647699236869812, -0.015334129333496094, 0.177334725856781, -0.09271524846553802, 0.12754225730895996, -0.029649095609784126, 0.10434305667877197, 0.12259869277477264, 0.1459072232246399, 0.13503903150558472, -0.12880393862724304, 0.20972198247909546, -0.23052646219730377, 0.07116372138261795, -0.1688728928565979, -0.048312216997146606, -0.030142227187752724, -0.07638457417488098, -0.01539898756891489, 0.0171334370970726, 0.04930339381098747, 0.09770137816667557, 0.07798124849796295, -0.05753128230571747, 0.05032629147171974, 0.12104104459285736, 0.04876694828271866, 0.08138074725866318, -0.0045969607308506966, 0.003559345379471779, 0.06286434084177017, 0.011426622048020363, 0.0661335438489914, -0.06809379905462265, 0.059777967631816864, 0.09585361182689667, -0.07706418633460999, 0.2116653174161911, -0.13933251798152924, -0.0032910495065152645, 0.06658809632062912, -0.07111027091741562, 0.04624961316585541, -0.1920747458934784, -0.22785356640815735, 0.16653266549110413, -0.04216202720999718, -0.13636761903762817, 0.13263678550720215, -0.026850316673517227, -0.022408731281757355, 0.11352099478244781, 0.12321533262729645, -0.12359853088855743, -0.15120409429073334, 0.05454540252685547, -0.08798863738775253, -0.06631863117218018, 0.011147161945700645, -0.154115229845047, 0.12151958048343658, 0.05857269838452339], "changes": {"1wk": -10.650885024122472, "1mo": -18.020443001466983}}, {"text": "Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update Corbus Pharmaceuticals Holdings, Inc. Thu, Nov 7, 2024, 3:00 PM 9 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. Completed Enrollment of Dose Escalation Part of Phase 1 Clinical Trial of its Next-Generation Nectin-4 Targeting ADC (CRB-701) - First data expected to be presented in Q1 2025 Presented New CRB-913 Pre-Clinical Data at Obesity Week 2024 - Phase 1 Trial Expected to Commence in Q1 2025 NORWOOD, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), an oncology and obesity company with a diversified portfolio, today provided a corporate update and reported financial results for the quarter ended September 30, 2024. \u201cWe continue to make steady and significant progress across our pipeline,\u201d said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. \u201cWe expect to report the first data from the CRB-701 U.S. bridging study in Q1 2025. This significant dataset will build on the encouraging clinical data presented at ASCO 2024 by CSPC, our development partner. The emerging efficacy and safety data presented at ASCO 2024 was promising and demonstrated the drug is clinically active with a differentiated safety profile.\u201d \u201cWe are also pleased with the continued development of CRB-913, our highly peripherally restricted CB1 inverse agonist for the treatment of obesity. We presented updated pre-clinical data at Obesity Week 2024 and expect to dose the first study participant in Q1 2025,\u201d concluded Dr. Cohen. Key Corporate Updates CRB-701: CRB-701 (SYS6002) is a next-generation ADC targeting Nectin-4 that contains a site-specific, cleavable linker and a precise drug antibody ratio of 2 using MMAE as the payload. The Company completed enrollment of the dose escalation part of its bridging Phase 1 clinical trial of CRB-701 (SYS6002) ( NCT06265727 ) that is being conducted in the U.S. and Europe. The three-part Phase 1 trial is evaluating the safety, pharmacokinetics and efficacy of CRB-701 in patients with advanced solid tumors known to be associated with high Nectin-4 expression. The Company expects to report the first data from the dose escalation study in Q1 2025, which will be the first Western data and provide a translational bridge to the encouraging Chinese data presented by our development partners, CSPC, at ASCO 2024. That data, based on 37 patients, demonstrated: 44% ORR and 78% DCR in metastatic urothelial cancer (\u201cmUC\u201d) and 43% ORR and 86% DCR in cervical cancer to date at doses \u2265 1.2mg/Kg. No dose limiting toxicities (\u201cDLTs\u201d) have been observed to date in doses up to and including 4.5 mg/Kg. Three cases of skin rash (including one grade 3) and one case of grade 1 neuropathy seen to date; all were resolved. Story Continues CRB-913: CRB-913 is a second-generation highly peripherally restricted CB1 receptor inverse agonist designed to treat obesity. The Company continues to conduct IND-enabling studies on CRB-913 and expects to dose the first patient in a Phase 1 study in Q1 2025. The Company presented new pre-clinical data (Poster Presentation) at Obesity Week 2024. Key findings include: Levels of CRB-913 in the brain were 15-fold lower than monlunabant in lean mice. Dose-response demonstrated for a range of 5 to 80 mg/Kg/day achieving up to 38% weight loss in diet-induced obesity (\u201cDIO\u201d) mice. Semaglutide treatment followed by its replacement with CRB-913 demonstrated continued weight loss in DIO mice. Switching from semaglutide to CRB-913 led to a doubling of fat loss in DIO mice. Prior published pre-clinical data Morningstar et al, Obesity Aug 2023 shows that CRB-913 provided additive weight loss when combined with incretin analogs in DIO mice. The totality of the pre-clinical data suggests potential uses as a monotherapy, combination therapy with incretins and as an induction/maintenance therapy. CRB-601: CRB-601 is a potentially best-in-class anti-\u03b1v\u03b28 monoclonal antibody that blocks the activation of TGF\u03b2 expressed on cancer cells in the tumor microenvironment. In pre-clinical models, CRB-601 demonstrates enhanced anti-tumor activity when combined with anti-PD-1 checkpoint inhibitor therapy compared to either single agent alone. The Company expects to dose the first patient in Q4 2024 for the Phase 1 portion of the CRB-601 clinical study NCT06603844 for the treatment of patients with advanced solid tumors. Financial Results for Quarter Ended September 30, 2024: The Company reported a net loss of approximately $13.8 million, or $1.15 per diluted share, for the three months ended September 30, 2024, compared to a net loss of approximately $10.1 million, or $2.27 per diluted share for the same period in 2023. Operating expenses increased by $6.0 million to approximately $15.5 million for the three months ended September 30, 2024, compared to $9.5 million in the comparable period in the prior year. The increase was primarily attributable to an increase of $3.2 million in CRB-701 clinical trial costs with our contract research organization (\"CRO\") and clinical sites, IND-enabling studies for CRB-913 of $1.0 million and higher compensation costs of $1.6 million mainly due to stock-based compensation expense. As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations through Q3 2027, based on the current planned expenditures. During the third quarter of 2024, the Company raised $35.6 million of net proceeds pursuant to the Company\u2019s ATM program by issuing 663,730 shares. In addition, on August 1, 2024, the Company\u2019s made a final $11.8 million loan payment and the loan has been fully paid off. About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company\u2019s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management\u2019s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cshould,\u201d \u201cwould\u201d and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company\u2019s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals smoran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com ---tables to follow--- Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share amounts) (Unaudited) For the Three Months Ended September\u00a030, For the Nine Months Ended September\u00a030, 2024 2023 2024 2023 Operating expenses: Research and development $ 10,808 $ 6,551 $ 23,435 $ 24,188 General and administrative 4,697 2,937 12,681 10,786 Total operating expenses 15,505 9,488 36,116 34,974 Operating loss (15,505 ) (9,488 ) (36,116 ) (34,974 ) Other income (expense), net: Other income, net 713 218 4,317 630 Interest income 1,189 217 2,757 711 Interest expense (381 ) (980 ) (1,872 ) (2,928 ) Change in fair value of derivative liability \u2014 \u2014 39 \u2014 Foreign currency transaction gain (loss), net 201 (20 ) 196 (21 ) Other income (expense), net 1,722 (565 ) 5,437 (1,608 ) Net loss $ (13,783 ) $ (10,053 ) $ (30,679 ) $ (36,582 ) Net loss per share, basic and diluted $ (1.15 ) $ (2.27 ) $ (2.92 ) $ (8.52 ) Weighted average number of common shares outstanding, basic and diluted 12,014,700 4,423,617 10,490,981 4,295,178 Comprehensive loss: Net loss $ (13,783 ) $ (10,053 ) $ (30,679 ) $ (36,582 ) Other comprehensive (loss) income: Change in unrealized gain on marketable debt securities 595 16 208 119 Total other comprehensive income 595 16 208 119 Total comprehensive loss $ (13,188 ) $ (10,037 ) $ (30,471 ) $ (36,463 ) Corbus Pharmaceuticals Holdings, Inc. Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) September\u00a030, 2024 (Unaudited) December\u00a031, 2023 ASSETS Current assets: Cash and cash equivalents $ 19,423 $ 13,724 Investments 139,939 7,182 Restricted cash 285 192 Prepaid expenses and other current assets 1,243 2,448 Total current assets 160,890 23,546 Restricted cash 385 478 Property and equipment, net 519 973 Operating lease right-of-use assets 2,377 3,063 Other assets \u2014 212 Total assets $ 164,171 $ 28,272 LIABILITIES AND STOCKHOLDERS\u2019 EQUITY Current liabilities: Notes payable $ \u2014 $ 301 Accounts payable 2,887 3,179 Accrued expenses 7,176 11,030 Derivative liability \u2014 39 Operating lease liabilities, current 1,562 1,437 Loan payable \u2014 15,908 Total current liabilities 11,625 31,894 Other long-term liabilities \u2014 44 Operating lease liabilities, noncurrent 2,048 3,239 Total liabilities 13,673 35,177 Stockholders\u2019 equity Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and December 31, 2023. \u2014 \u2014 Common stock, $0.0001 par value; 300,000,000 shares authorized, 12,179,482 and 4,423,683 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 1 \u2014 Additional paid-in capital 617,653 429,780 Accumulated deficit (467,363 ) (436,684 ) Accumulated other comprehensive gain (loss) 207 (1 ) Total stockholders\u2019 equity (deficit) 150,498 (6,905 ) Total liabilities and stockholders\u2019 equity $ 164,171 $ 28,272 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-11-07T15:00:00", "sentiment": {"score": 0.5428355988115072, "confidence": 0.5522971749305725, "probabilities": {"positive": 0.5522971749305725, "negative": 0.009461576119065285, "neutral": 0.4382411539554596}}, "embedding": [-0.09715259075164795, -0.0847759023308754, -0.08851391822099686, -0.061564646661281586, 0.008535683155059814, -0.046003442257642746, -0.1600298285484314, 0.16601547598838806, 0.020276851952075958, 0.002489703707396984, -0.14222414791584015, -0.06014258414506912, 0.01843186840415001, -0.006981126964092255, 0.01834428310394287, -0.0034842267632484436, 0.10961195826530457, -0.022169318050146103, -0.028962329030036926, 0.006262300536036491, -0.0415739081799984, 0.049752380698919296, 0.0029303263872861862, 0.15133856236934662, -0.08645850419998169, -0.17157500982284546, -0.053923849016427994, -0.004779274109750986, -0.16133756935596466, -0.032411813735961914, 0.08103598654270172, 0.05003608018159866, -0.02325570210814476, -0.025771476328372955, -0.07021863758563995, -0.05368485674262047, -0.1073063462972641, -0.09762918949127197, -0.05585121735930443, -0.014755014330148697, -0.02176554501056671, 0.028882239013910294, -0.10428230464458466, 0.15017512440681458, 0.053667254745960236, -0.2179657518863678, -0.17645053565502167, 0.08142586797475815, 0.01795855723321438, 0.1943853497505188, -0.040367964655160904, -0.041344691067934036, -0.05623249709606171, 0.26115134358406067, -0.029969319701194763, 0.03840821608901024, -0.18252825736999512, -0.006581336725503206, 0.10202546417713165, -0.0034554162994027138, -0.028484035283327103, 0.021218009293079376, 0.08287772536277771, 0.06338663399219513, 0.09310920536518097, 0.06286783516407013, -0.09801339358091354, -0.10406175255775452, 0.0260116308927536, 0.028630049899220467, 0.08500321209430695, -0.12700092792510986, -0.06616213917732239, 0.05861945450305939, -0.06126474216580391, 0.17121824622154236, 0.01668880134820938, 0.17002516984939575, 0.07418795675039291, -0.12197838723659515, 0.004614557139575481, 0.11607319861650467, 0.14871735870838165, 0.003133460646495223, 0.00010446365922689438, 0.01441860105842352, -0.018539749085903168, 0.16835571825504303, -0.019370222464203835, 0.05485522001981735, 0.13977788388729095, 0.0657045990228653, 0.06546606868505478, 0.10523372143507004, -0.10056941956281662, -0.06417301297187805, -0.06933905929327011, 0.016546174883842468, -0.044396739453077316, -0.008912059478461742, -0.0036685997620224953, 0.13874377310276031, -0.06698756664991379, -0.07679518312215805, -0.008361579850316048, -0.05919289216399193, 0.07885296642780304, 0.09806587547063828, 0.05134421959519386, 0.035705387592315674, -0.04577784985303879, 0.040680911391973495, 0.027569632977247238, -0.07126069813966751, -0.044762156903743744, 0.12055955827236176, 0.006395877338945866, 0.004637059755623341, 0.16139158606529236, -0.02600342407822609, 0.061541132628917694, -0.013112920336425304, -0.014469269663095474, -0.1675722897052765, 0.06658583879470825, 0.04576706886291504, -0.11228145658969879, 1.1551436048736767e-32, -0.007840385660529137, -0.09440933167934418, 0.13314850628376007, 0.0853549987077713, -0.04589918255805969, -0.05459924787282944, -0.0075689926743507385, 0.02013377659022808, -0.15081331133842468, -0.13978470861911774, -0.09677407145500183, 0.014104858972132206, 0.018100673332810402, 0.11891588568687439, -0.13031649589538574, -0.20052406191825867, -0.002114446833729744, 0.07637953758239746, 0.01268343348056078, -0.050997283309698105, -0.04238549619913101, 0.07731203734874725, -0.03475871682167053, 0.10040855407714844, -0.023899566382169724, 0.08163465559482574, -0.03212626650929451, 0.12768100202083588, -0.02320495992898941, 0.07150374352931976, -0.1792619228363037, 0.01897583156824112, -0.002014659810811281, -0.07985013723373413, -0.1348435878753662, -0.07648622244596481, -0.037638068199157715, -0.15586338937282562, -0.07861175388097763, 0.15067897737026215, 0.11646567285060883, 0.0227343812584877, -0.012605554424226284, -0.20317429304122925, 0.10832607746124268, -0.036759842187166214, -0.07364603132009506, 0.07772433757781982, -0.019483596086502075, -0.005392261780798435, -0.07436098903417587, -0.03138280659914017, -0.011176041327416897, 0.042462605983018875, -0.0446530357003212, -0.01741768792271614, -0.12794652581214905, -0.10065913200378418, 0.1591060906648636, 0.003680785186588764, 0.05750206485390663, 0.07193247228860855, -0.07396286725997925, 0.09605558961629868, -0.05411490797996521, 0.0870322734117508, -0.07716409116983414, -0.1445920616388321, -0.0874498039484024, 0.05834091454744339, 0.010493088513612747, -0.08140086382627487, 0.11548186838626862, 0.05409035086631775, 0.19609785079956055, -0.05911020189523697, 0.07633364945650101, 0.00547460000962019, -0.02010798454284668, 0.07748809456825256, 0.02673916146159172, 0.01663464494049549, -0.03883003816008568, 0.12627211213111877, 0.011486111208796501, -0.16364997625350952, -0.00016076117753982544, -0.015181654132902622, -0.07066095620393753, -0.021332819014787674, 0.07384079694747925, -0.014041327871382236, -0.10916918516159058, 0.1991390585899353, -0.03699305281043053, -9.922019411556668e-33, -0.05776936188340187, -0.028785575181245804, 0.0471503771841526, -0.05801839008927345, -0.05347513407468796, 0.0717930942773819, 0.09264890104532242, -0.2276305854320526, 0.20159801840782166, -0.17105883359909058, 0.1365637183189392, -0.04082852602005005, -0.07266567647457123, -0.032656725496053696, -0.009225936606526375, 0.09479229152202606, -0.05374526232481003, -0.07144811749458313, -0.11385419964790344, 0.05123566836118698, 0.08910071104764938, 0.02933071367442608, -0.1238112673163414, 0.029769614338874817, 0.025038402527570724, 0.04733479022979736, 0.16392937302589417, 0.1095525324344635, 0.10001517087221146, -0.04444161430001259, -0.07527647912502289, 0.005597428418695927, -0.21141129732131958, 0.12216299772262573, -0.06394285708665848, -0.027000408619642258, 0.08548666536808014, -0.08813556283712387, -0.048307400196790695, -0.18205362558364868, 0.059858888387680054, 0.09968438744544983, -0.10044026374816895, -0.029110141098499298, 0.03707604855298996, -0.03997493535280228, 0.11237159371376038, 0.026933908462524414, 0.1201522946357727, -0.02207467518746853, 0.008514882065355778, -0.0036440996918827295, 0.009167352691292763, 0.05299341678619385, 0.02098759636282921, 0.037844885140657425, 0.03035145252943039, -0.06860055029392242, 0.04046887904405594, -0.06721004843711853, 0.027574647217988968, 0.17408129572868347, 0.07858014851808548, 0.024479646235704422, 0.12757153809070587, 0.16699029505252838, 0.06619495898485184, 0.02761511504650116, -0.015833668410778046, -0.10374432802200317, -0.004149987827986479, -0.12152920663356781, 0.015149544924497604, -0.0690758153796196, 0.04605511203408241, -0.005268334411084652, -4.857964813709259e-05, -0.10111380368471146, -0.2260373830795288, -0.018990475684404373, -0.007890220731496811, -0.16434162855148315, 0.04897816479206085, 0.04598696902394295, -0.020633181557059288, 0.13439397513866425, -0.04947361722588539, -0.01719602569937706, -0.020891062915325165, 0.11013112217187881, -0.12710797786712646, -0.043998632580041885, -0.13086307048797607, 0.1855827271938324, 0.13274335861206055, -9.990613136778848e-08, 0.08249726891517639, 0.03906259313225746, 0.08035209774971008, -0.06368407607078552, 0.06244651600718498, 0.04146363586187363, -0.017810937017202377, -0.07026111334562302, -0.05354481562972069, 0.09739315509796143, 0.06689866632223129, 0.12638239562511444, -0.04254499077796936, 0.028414607048034668, -0.11689220368862152, 0.13720747828483582, -0.06949377804994583, 0.010529759339988232, 0.020777873694896698, 0.010307487100362778, -0.18882080912590027, 0.001983807422220707, 0.1529962569475174, -0.05236433446407318, 0.09198146313428879, -0.09683218598365784, -0.007707308046519756, 0.2029983103275299, 0.13892045617103577, 0.0022875280119478703, -0.02362075448036194, 0.005740556865930557, 0.025712450966238976, -0.04009328782558441, 0.0010007740929722786, -0.05246879905462265, 0.0730300098657608, 0.10149946063756943, 0.01166639942675829, 0.16624164581298828, -0.026714997366070747, 0.009779882617294788, 0.021312516182661057, 0.013976100832223892, 0.018749739974737167, -0.1195211410522461, -0.10743442922830582, 0.11252492666244507, -0.05854722484946251, -0.11806230247020721, -0.048739902675151825, -0.0300290510058403, -0.06161477044224739, -0.012765474617481232, 0.009582974016666412, 0.10234617441892624, -0.14304006099700928, -0.1195816844701767, 0.043761201202869415, -0.09723366796970367, 0.0832802802324295, -0.10925371944904327, 0.07664303481578827, 0.06382974982261658], "changes": {"1wk": -1.889850825154838, "1mo": -17.60259259343176}}, {"text": "Corbus Pharmaceuticals to Present at the 7th Annual Evercore HealthCONx Conference Corbus Pharmaceuticals Holdings, Inc. Thu, Nov 21, 2024, 4:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. NORWOOD, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 7 th Annual Evercore HealthCONx Conference to be held December 3-5, 2024 in Coral Gables, FL. 7 th Annual Evercore HealthCONx Conference Format: Fireside chat and one-on-one investor meetings Date: December 3, 2024 Time: 4:15 p.m. ET Webcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on Twitter , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Story Continues All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals Sean.moran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-11-21T16:00:00", "sentiment": {"score": 0.05560267623513937, "confidence": 0.06673098355531693, "probabilities": {"positive": 0.06673098355531693, "negative": 0.011128307320177555, "neutral": 0.9221407175064087}}, "embedding": [-0.01368407066911459, -0.06325894594192505, -0.13163337111473083, -0.09929554164409637, 0.07472231239080429, 0.04914698749780655, -0.09474606066942215, 0.15362152457237244, 0.062238339334726334, 0.009050112217664719, -0.14552760124206543, -0.0013648841995745897, 0.01648005098104477, 0.006144950166344643, -0.012114463374018669, -0.01126410998404026, 0.07312817871570587, -0.05957596004009247, -0.013522975146770477, 0.00886616762727499, -0.007510852068662643, 0.1188596785068512, 0.03660498932003975, 0.12015499919652939, -0.15056414902210236, -0.13954412937164307, -0.11768332868814468, -0.04845406115055084, -0.20493178069591522, 0.030555102974176407, 0.11514727026224136, 0.07979568839073181, -0.04021851718425751, 0.028836000710725784, 0.012140740640461445, -0.03769603371620178, -0.12191364914178848, -0.0481702983379364, 0.022212985903024673, 0.07311281561851501, -0.015619214624166489, 0.07660910487174988, -0.06023360788822174, 0.07500648498535156, 0.0019016759470105171, -0.24512764811515808, -0.1710948944091797, 0.09454398602247238, 0.10295352339744568, 0.14684008061885834, -0.10072215646505356, -0.04849234223365784, -0.07469882071018219, 0.20867514610290527, -0.03552764654159546, 0.20410802960395813, -0.2856593132019043, 0.006436880677938461, 0.11221355199813843, -0.05982860177755356, 0.02090279571712017, 0.043279435485601425, 0.19989827275276184, 0.17465710639953613, 0.11494038999080658, 0.0679631233215332, -0.08772949874401093, 0.011225073598325253, 0.02541375905275345, -0.047248438000679016, 0.20864337682724, -0.14131855964660645, -0.0574834868311882, 0.034411028027534485, -0.020093252882361412, 0.16467702388763428, 0.050485849380493164, 0.18702496588230133, 0.11309205740690231, -0.0815620869398117, -0.027630258351564407, 0.1282348483800888, 0.246163472533226, -0.01207959745079279, -0.112822987139225, 0.011075291782617569, -0.003693019039928913, 0.08765377104282379, 0.08145271986722946, -0.0015255147591233253, 0.1610404998064041, -0.03774121403694153, 0.07318107783794403, 0.12473735213279724, -0.039145566523075104, -0.12546324729919434, -0.030041325837373734, 0.00932620745152235, -0.05045776814222336, -0.06238171458244324, -0.027528539299964905, 0.07651232182979584, -0.1171049028635025, -0.12054817378520966, -0.04422399401664734, -0.03219683840870857, 0.011138973757624626, 0.1598144918680191, 0.0723368376493454, 0.020417388528585434, -0.11267013102769852, 0.10817576199769974, 0.007267003878951073, -0.09407676756381989, 0.038694217801094055, 0.1596887707710266, 0.0033294837921857834, -0.029536927118897438, 0.09922122955322266, -0.11864939332008362, 0.05321749299764633, -0.05790972709655762, -0.00747329369187355, -0.11532070487737656, 0.007585928775370121, 0.038706209510564804, -0.1852998435497284, 8.866807520182271e-33, 0.01688060536980629, -0.05301298201084137, 0.1464025378227234, 0.06750930100679398, -0.0148906409740448, -0.0723126083612442, 0.011799106374382973, -0.006983082741498947, -0.18257951736450195, -0.07733795046806335, -0.1503390520811081, 0.1315857172012329, 0.016703449189662933, 0.093123659491539, -0.08378782868385315, -0.15491226315498352, -0.018604261800646782, 0.05627662315964699, 0.07525131851434708, -0.1007358655333519, -0.08181385695934296, 0.09452256560325623, -0.009531810879707336, 0.12162995338439941, 0.015754232183098793, 0.08663461357355118, -0.0597822368144989, 0.08806119114160538, 0.033454008400440216, 0.07934519648551941, -0.1583847552537918, -0.021415095776319504, -0.031819384545087814, -0.1295400708913803, -0.07601030170917511, -0.033678919076919556, -0.12813803553581238, -0.17135800421237946, -0.08650773018598557, 0.04807482287287712, -0.02820616215467453, -0.0020387410186231136, -0.10577023029327393, -0.16665634512901306, 0.0962916761636734, -0.013173764571547508, -0.0936703234910965, 0.09070175886154175, -0.02875830978155136, -0.07444728165864944, -0.03875233605504036, 0.03776492178440094, 0.013175707310438156, 0.017428338527679443, -0.05481979250907898, -0.05386986583471298, -0.10937590897083282, -0.073754221200943, 0.20634910464286804, 0.054986417293548584, 0.032178472727537155, 0.01612696796655655, -0.10193134844303131, 0.02443135529756546, -0.10480518639087677, 0.061434220522642136, -0.11317136138677597, -0.1258205771446228, -0.055687516927719116, 0.06681521981954575, 0.023374946787953377, -0.00179877202026546, 0.07535111904144287, -0.04228317365050316, 0.15210610628128052, -0.0916108712553978, 0.04452957585453987, 0.004797063767910004, -0.07061401009559631, 0.10870414972305298, 0.02668110653758049, -0.07018006592988968, -0.032728590071201324, 0.11345944553613663, 0.06883672624826431, -0.2160009741783142, -0.021653102710843086, 0.044812947511672974, -0.031424738466739655, 0.05399307608604431, 0.011234184727072716, -0.02036435902118683, -0.022122185677289963, 0.18660306930541992, -0.06352130323648453, -7.043704678817184e-33, -0.10379110276699066, -0.17131319642066956, 0.005479834042489529, -0.011961683630943298, 0.03475165739655495, 0.017876021564006805, 0.07372146099805832, -0.159098282456398, 0.14192193746566772, -0.19113102555274963, 0.03134419023990631, -0.019347919151186943, -0.10550922155380249, -0.06913433223962784, -0.08800690621137619, 0.1097341924905777, 0.01535837072879076, 0.018861722201108932, -0.1455504298210144, 0.01115658599883318, 0.04828701540827751, 0.04748686030507088, -0.0882859081029892, 0.027452386915683746, -0.05310124531388283, 0.1319570541381836, 0.0708341971039772, 0.07425300776958466, 0.06960988789796829, 0.025633135810494423, -0.08058878779411316, 0.10991938412189484, -0.2921799123287201, 0.19404342770576477, -0.08165687322616577, 0.021844925358891487, 0.0489887073636055, -0.13424062728881836, 0.06255993992090225, -0.17639636993408203, 0.11335702240467072, 0.0758126750588417, -0.06359631568193436, 0.004859530832618475, 0.10222367942333221, 0.0021045776084065437, 0.05646064132452011, 0.06219262629747391, 0.10011310875415802, 0.1635117083787918, -0.051231540739536285, -0.025453053414821625, 0.02966204099357128, 0.09835691750049591, -0.011733626015484333, 0.051238786429166794, -0.04871572554111481, -0.048844583332538605, 0.06197711080312729, -0.05098909139633179, 0.04872151091694832, 0.11834794282913208, -0.01794378273189068, 0.08254215121269226, 0.128382608294487, 0.10831616073846817, 0.06310292333364487, 0.14810942113399506, 0.04132372885942459, -0.11983329057693481, 0.10711488127708435, -0.14257942140102386, 0.001455867663025856, -0.07388985902070999, 0.012495514005422592, 0.0784042477607727, -0.04417683929204941, -0.10198512673377991, -0.16642245650291443, 0.13005831837654114, -0.026900123804807663, -0.04357324168086052, 0.09770114719867706, 0.08529184013605118, 0.04262233525514603, 0.1585337370634079, -0.012821181677281857, 0.0024757906794548035, -0.03759431093931198, 0.07433083653450012, -0.0972464382648468, -0.1012457013130188, -0.05396657437086105, 0.14786632359027863, 0.10722944140434265, -9.906227660394507e-08, 0.03513137251138687, -0.03702165558934212, 0.05844691023230553, -0.046790964901447296, 0.1307203322649002, -0.007971648126840591, 0.06725132465362549, -0.07838919758796692, -0.05663921684026718, 0.12512609362602234, 0.11282213032245636, 0.11457892507314682, -0.1099763959646225, -0.008248274214565754, -0.09618432819843292, 0.03746803104877472, -0.149403914809227, 0.002448062412440777, -0.005881094373762608, -0.033641573041677475, -0.09835955500602722, -0.009309752844274044, 0.15921835601329803, 0.07557026296854019, 0.01435849629342556, -0.10449960827827454, 0.021525975316762924, 0.08486488461494446, 0.10799084603786469, 0.07370346784591675, -0.11172567307949066, 0.06834505498409271, 0.01575753465294838, -0.014985601417720318, -0.020119482651352882, -0.12971864640712738, 0.09353205561637878, 0.1259051263332367, 0.014422480948269367, 0.13675564527511597, -0.12791761755943298, 0.017424684017896652, 0.10019084066152573, -0.020097102969884872, -0.04014476388692856, -0.16569717228412628, -0.03424373269081116, 0.12461037188768387, -0.00018530013039708138, -0.11778582632541656, -0.06522400677204132, -0.044275619089603424, -0.07791861146688461, -0.014237459748983383, -0.08924467861652374, 0.05385168641805649, -0.13116469979286194, -0.14663270115852356, 0.04269377887248993, -0.16080687940120697, 0.021430596709251404, -0.10261945426464081, 0.18209657073020935, 0.06941720098257065], "changes": {"1wk": 5.4393297807016445, "1mo": -22.295275817668866}}, {"text": "Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference Corbus Pharmaceuticals Holdings, Inc. Tue, Nov 12, 2024, 4:00 PM 3 min read In This Article: CRBP -2.86% Corbus Pharmaceuticals Holdings, Inc. NORWOOD, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (\u201cCorbus\u201d or the \u201cCompany\u201d), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the Jefferies London Healthcare Conference to be held November 19-21, 2024 in London, UK. Jefferies London Healthcare Conference Format: Fireside chat and one-on-one investor meetings Date: November 19, 2024 Time: 10:30 a.m. GMT Webcast: Click here About Corbus Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus\u2019 pipeline includes CRB-701, a next generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody which blocks the activation of TGF\u03b2 expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com . Connect with us on Twitter , LinkedIn and Facebook . Forward-Looking Statements This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's trial results, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, \"expect,\" \"anticipate,\" \"intend,\" \"plan,\" \"believe,\" \"estimate,\" \"potential,\u201d \"predict,\" \"project,\" \"should,\" \"would\" and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Story Continues All product names, logos, brands and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies. INVESTOR CONTACT: Sean Moran Chief Financial Officer Corbus Pharmaceuticals Sean.moran@corbuspharma.com Bruce Mackle Managing Director LifeSci Advisors, LLC bmackle@lifesciadvisors.com View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRBP", "date": "2024-11-12T16:00:00", "sentiment": {"score": 0.04467946104705334, "confidence": 0.05658277869224548, "probabilities": {"positive": 0.05658277869224548, "negative": 0.011903317645192146, "neutral": 0.9315139055252075}}, "embedding": [-0.02031528390944004, -0.06855252385139465, -0.0965893566608429, -0.11890097707509995, 0.020891649648547173, 0.04082679748535156, -0.03595037758350372, 0.16563600301742554, 0.07693462818861008, 0.02329554595053196, -0.16078153252601624, 0.03771035373210907, 0.01853637956082821, 0.006058061961084604, -0.014493430033326149, -0.01068570464849472, 0.06130059063434601, -0.05514344573020935, -0.05119791999459267, -0.004844615235924721, -0.00732586532831192, 0.13587211072444916, 0.021595675498247147, 0.12289626896381378, -0.14028142392635345, -0.11761258542537689, -0.07374255359172821, -0.041426800191402435, -0.2104431837797165, 0.029219504445791245, 0.12359203398227692, 0.05610014498233795, -0.022499309852719307, 0.015973545610904694, 0.001441123429685831, -0.009279780089855194, -0.11113230884075165, -0.04233158379793167, 0.03901716694235802, 0.0561264306306839, 0.00985894538462162, 0.05952794849872589, -0.06812603026628494, 0.07192820310592651, 0.009749614633619785, -0.184609055519104, -0.1278398334980011, 0.06788457930088043, 0.08663477003574371, 0.11057703197002411, -0.07833515107631683, -0.05874446779489517, -0.04857363551855087, 0.1803043782711029, -0.06728199124336243, 0.1311933845281601, -0.26435336470603943, 0.007872816175222397, 0.10216794162988663, -0.07353637367486954, 0.01591922715306282, 0.061743151396512985, 0.166631281375885, 0.17045347392559052, 0.08781348168849945, 0.07107967883348465, -0.049016088247299194, -0.01611461117863655, 0.01571430079638958, -0.056263621896505356, 0.16322699189186096, -0.14048703014850616, -0.05899861454963684, 0.026248883455991745, -0.07727132737636566, 0.15082108974456787, 0.0763838067650795, 0.1523410975933075, 0.09987904131412506, -0.10093065351247787, -0.015185046941041946, 0.11128081381320953, 0.21899321675300598, -0.022984176874160767, -0.11562223732471466, -0.028276480734348297, 0.009158692322671413, 0.07162629812955856, 0.06642348319292068, 0.015582812018692493, 0.1815832257270813, -0.03804393857717514, 0.07779531925916672, 0.12962710857391357, -0.056889817118644714, -0.13087911903858185, -0.006183859426528215, 0.004823635797947645, -0.06632189452648163, -0.020775066688656807, -0.03618789464235306, 0.11151588708162308, -0.10799214243888855, -0.08662895113229752, -0.06104373186826706, -0.049627818167209625, 0.0003331114421598613, 0.1194072812795639, 0.06033718213438988, 0.0021066057961434126, -0.12067141383886337, 0.10885118693113327, -0.012435704469680786, -0.08994203805923462, 0.032177895307540894, 0.1625349074602127, 0.003371531143784523, -0.023535877466201782, 0.10799161344766617, -0.11778175830841064, 0.05931326001882553, -0.03691400587558746, -0.01446263026446104, -0.14061249792575836, -0.0024991920217871666, 0.057737357914447784, -0.1980585902929306, 7.174837685807133e-33, -0.005631398409605026, -0.053966619074344635, 0.1493845283985138, 0.07100250571966171, -0.01534015592187643, -0.05739571899175644, -0.02186545543372631, 0.020413219928741455, -0.1495475172996521, -0.08518756926059723, -0.1524045467376709, 0.10734859108924866, 0.017641602084040642, 0.053354714065790176, -0.10771162807941437, -0.06632883846759796, -0.04108230397105217, 0.041510432958602905, 0.07881638407707214, -0.06776820123195648, -0.107430100440979, 0.1000756174325943, 0.0089121637865901, 0.1102561429142952, -0.0050520217046141624, 0.08138318359851837, -0.060122761875391006, 0.07106102257966995, 0.04343339800834656, 0.08314099907875061, -0.14502592384815216, 0.004767103120684624, -0.041164226830005646, -0.09676831215620041, -0.07047220319509506, -0.03857538476586342, -0.14551126956939697, -0.178599551320076, -0.05796182155609131, 0.03691501542925835, -0.03894191235303879, -0.04191827401518822, -0.08991482853889465, -0.15614259243011475, 0.10774846374988556, 0.028334161266684532, -0.09998014569282532, 0.03935021162033081, -0.03337552398443222, -0.03859981149435043, -0.01626726984977722, 0.039249081164598465, -0.009130326099693775, -0.014205318875610828, -0.044499579817056656, -0.0559898316860199, -0.11398302018642426, -0.07123789936304092, 0.1709517240524292, 0.06459168344736099, 0.04861169308423996, 0.08866611868143082, -0.06369178742170334, 0.027077212929725647, -0.1050821915268898, 0.03237231820821762, -0.10966058075428009, -0.1123722717165947, -0.06901053339242935, 0.04083488881587982, 0.035710498690605164, 0.024756107479333878, 0.09666920453310013, -0.021756064146757126, 0.13003256916999817, -0.09841087460517883, 0.040892768651247025, 0.02601829543709755, -0.044815633445978165, 0.08140535652637482, 0.02793188951909542, -0.08776576071977615, -0.016385767608880997, 0.10145506262779236, 0.06268873810768127, -0.18516570329666138, 0.001321227289736271, 0.04994136095046997, -0.03325006365776062, 0.038160402327775955, -0.029889050871133804, -0.014940870925784111, -0.05684785172343254, 0.20655184984207153, -0.033951375633478165, -6.943525376820262e-33, -0.10952316224575043, -0.15187327563762665, 0.00571937020868063, -0.009018076583743095, 0.003780711442232132, 0.020246237516403198, 0.09139876067638397, -0.14368942379951477, 0.13866013288497925, -0.14440004527568817, 0.00973469391465187, -0.01357070729136467, -0.06876229494810104, -0.06627551466226578, -0.09001576900482178, 0.06658410280942917, 0.009541379287838936, -0.022047530859708786, -0.14759430289268494, 0.013925332576036453, 0.06028720736503601, 0.09101010859012604, -0.0726599171757698, 0.04538559168577194, -0.043045252561569214, 0.10381722450256348, 0.06505768746137619, 0.0753784030675888, 0.07129421085119247, 0.006088816560804844, -0.0813787579536438, 0.13882678747177124, -0.26826536655426025, 0.1677381992340088, -0.08203725516796112, 0.018238969147205353, 0.07649687677621841, -0.14676541090011597, 0.05395402014255524, -0.1622389256954193, 0.09326933324337006, 0.07398650050163269, -0.039351727813482285, 0.01994624175131321, 0.09385697543621063, 0.0030290521681308746, 0.06636964529752731, 0.06798873841762543, 0.1200798898935318, 0.11926144361495972, -0.04935767501592636, -0.012666533701121807, 0.042746465653181076, 0.07244354486465454, -0.013413548469543457, 0.05787437781691551, -0.04628978669643402, -0.07022418826818466, 0.07453963905572891, -0.016915852203965187, 0.0258401557803154, 0.10956940054893494, -0.01437797024846077, 0.05072661116719246, 0.10154882818460464, 0.08024232089519501, 0.06606924533843994, 0.12206666171550751, 0.07588212937116623, -0.11520631611347198, 0.11049482226371765, -0.1742907464504242, 0.013829583302140236, -0.07886850833892822, 0.030382879078388214, 0.06677638739347458, -0.034208498895168304, -0.142208993434906, -0.18939092755317688, 0.08925428986549377, 0.035226114094257355, -0.06675931811332703, 0.12491041421890259, 0.0765908882021904, 0.02831914834678173, 0.10984261333942413, -0.027039898559451103, -0.0005454644560813904, -0.04873741418123245, 0.031398095190525055, -0.09938369691371918, -0.09087957441806793, -0.06806463748216629, 0.14576518535614014, 0.08253826200962067, -9.946013790340658e-08, 0.028738107532262802, -0.05956991761922836, 0.06829147040843964, -0.06368152797222137, 0.11608520150184631, -0.0037047937512397766, 0.03358330577611923, -0.03767465800046921, -0.05507495254278183, 0.11303463578224182, 0.10306119173765182, 0.11273013055324554, -0.11901240795850754, 0.03564042970538139, -0.11702147126197815, 0.06188628077507019, -0.18676403164863586, -0.017618568614125252, -0.009693428874015808, 0.0018402934074401855, -0.09492059051990509, -0.01515668909996748, 0.10920708626508713, 0.0700121745467186, 0.06217404827475548, -0.10875925421714783, 0.006048229523003101, 0.09742936491966248, 0.06534451246261597, 0.05178669095039368, -0.08111885190010071, 0.09023921191692352, 0.05025731772184372, 0.010741429403424263, -0.02697567641735077, -0.15526868402957916, 0.10957541316747665, 0.12524937093257904, 0.021076306700706482, 0.09016071259975433, -0.122530996799469, 0.00019081402570009232, 0.08483536541461945, -0.014397864229977131, -0.04986455291509628, -0.1439892053604126, -0.0536847785115242, 0.1331922858953476, -0.006510212551802397, -0.1174762099981308, -0.021518919616937637, -0.03464055806398392, -0.03361675888299942, 0.01846936345100403, -0.06862099468708038, 0.026837337762117386, -0.12066857516765594, -0.1296432912349701, 0.03772026672959328, -0.15029621124267578, 0.03065107949078083, -0.08906681835651398, 0.15957342088222504, 0.050835251808166504], "changes": {"1wk": -6.577481995809574, "1mo": -11.761430030873743}}]